Oral NIASPAN extended-release nicotinic acid — added to usual diabetes care × HbA1c increase in adults with stable type 2 diabetes and dyslipidemia

Required evidence, verification status and materials actually read
Item	AVerification status	BReading scope	CReview item	DCurrent findings	EWhy unverified	FRequired materials and conditions	GFurther research
1	Met	Full text not readStored summary read	N01 · Comparative harm: HbA1c increaseWhich population, intervention, comparator, time period and endpoint define the comparative harm claim?Required	The selected original claim concerns adults with stable type 2 diabetes and dyslipidemia and an increase in HbA1c. It is a quantitative harm question comparing the oral NIASPAN ER add-on strategy with matching placebo over a total of 16 weeks. S01	The actual claim identity and comparison scope are verified. This status does not establish the clinical importance of the increase or harm from all niacin interventions.	Material linking the identity of the current claim with the actual population, intervention, comparator, endpoint and time point	Compare the current manuscript with the trial's actual comparison, and record the reason and the scope before and after any boundary change.
2	Met	Full text not readStored summary read	N02 · Comparative harm: HbA1c increaseAre the actual ingredient, product, release formulation and route verified?Required	The intervention is NIASPAN (Kos), single-ingredient nicotinic acid in ER oral tablets. Nicotinamide, NR, NMN, no-flush preparations, nicotine and IR/SR substitutes are not treated as the same intervention. Equivalence of a separate salt was not verified. S01 S06	The selected ingredient, product, release formulation, route and exclusions are verified. This does not mean that the manufacturing process, batch or excipients have also been verified.	The core trial's product name, ingredient, release formulation and route, and the corresponding locations in the official product description	Compare the trial product's ingredient and release formulation with the original description, and consider other molecules/formulations only through their own direct evidence.
3	Unverified	Full text not readStored summary read	N03 · Comparative harm: HbA1c increaseIs the actual information on manufacturing origin, batch and excipients verified?Supplementary; required for detailed product identity	The raw material's manufacturing origin, such as synthesis or fermentation, the batch and the exact excipients are unverified. Plant-part information has a null value/not_applicable status, whereas manufacturing origin has a null value/unverified status; these are different. S01 S06	The retained material does not provide evidence that establishes the product's detailed manufacturing information. Do not erase this gap by using the Not applicable designation for this chemical ingredient's plant-part information.	Specifications for the trial product's manufacturing process, raw-material origin, batch and excipients	If permitted product material is obtained, compare it with the trial batch and do not inherit information from another product.
4	Met	Full text not readStored summary read	N04 · Comparative harm: HbA1c increaseAre the trial's diagnosis, stability, age and inclusion/exclusion criteria verified?Required	Participants were men and women aged 21 or older with stable type 2 diabetes and dyslipidemia. Two measurements showed HbA1c ≤ 9% and fasting glucose ≤ 200 mg/dL. Exclusions recorded included relevant liver disease, a history of gout or peptic ulcer, and thiazolidinedione use. S01	This verifies the population and entry criteria specified in the original material. It does not verify the magnitude of harm in all people with diabetes or in excluded vulnerable groups.	Inclusion/exclusion criteria, diagnosis, baseline-characteristics table and material verifying stability	Compare the actual recruited population's diagnoses and entry criteria with the claim's target population, and keep direct results in other populations separate.
5	Not reported	Full text not readStored summary read	N05 · Comparative harm: HbA1c increaseAre baseline niacin status, deficiency classification and total dietary intake verified?Supplementary; required for interpreting deficiency/total exposure	Baseline niacin concentrations, deficiency classification and total dietary niacin could not be verified in the text accessed at the time. This trial is not defined as a deficiency-treatment trial. S01	The original record of unknowns specifies the scope as not_reported_in_accessed_text. The external full text was not read in this review, so this is not extended to nonreporting throughout the current full text.	Baseline niacin measurements, deficiency-classification criteria and data on total dietary niacin	Review direct material while distinguishing baseline status from drug and dietary exposure, and treat results of deficiency treatment as a separate question.
6	Met	Full text not readStored summary read	N06 · Comparative harm: HbA1c increaseAre the actual planned titration, target dose and dosing frequency verified?Required	The schedule was 1 dose per 1 day at bedtime, titrated through week 1 at 375 mg/day, week 2 at 500 mg/day, week 3 at 750 mg/day and week 4 at 1,000 mg/day, followed by a target for weeks 5–16 of 1,500 mg/day. The target tablet count was recorded as two 750 mg tablets. S01	The nominal plan in the original treatment schedule is verified. This does not verify that every participant actually maintained this dose.	Trial treatment schedule, target dose, tablet count and data on actual adherence/dose reached	Compare planned administration with actual treatment histories, distinguishing nominal dose, dose reached and cumulative exposure.
7	Met	Full text not readStored summary read	N07 · Comparative harm: HbA1c increaseAre the titration period, target-dose period and total follow-up period separately identified and verified?Required	The planned total treatment of 16 weeks includes 4 weeks of titration, and the target-dose period is 12 weeks. Long-term follow-up for the selected HbA1c question has no recorded value (null). S01	The actual planned timeline is specified. The 16-week results do not verify persistence, rare harms or long-term complications.	Schedules for treatment, titration, target-dose maintenance and end of follow-up, together with long-term follow-up material	Link the timeline to actual exposure and measurement schedules, and examine persistence after discontinuation or long-term outcomes through separate follow-up.
8	Partly verified	Full text not readStored summary read	N08 · Comparative harm: HbA1c increaseIs the actual composition of the matching placebo verified?Required	There is a record of a randomized, double-blind comparison using matching placebo. Its exact composition beyond the description of matching placebo is unverified. S01	The comparison type is verified, but details of the actual composition, appearance and establishment of blinding were not verified.	Material on placebo manufacture, composition, appearance, corresponding tablets and blinding assessment	Compare the placebo description with the trial product, distinguishing the unverified details of composition and blinding.
9	Met	Full text not readStored summary read	N09 · Comparative harm: HbA1c increaseAre the common policies on diabetes-treatment adjustment, statins and aspirin verified?Required	Under the common diet and diabetes-care policy, diabetes medications could be increased or added. Only existing statin users continued statins; they were not common treatment given to everyone. Other lipid-lowering medications underwent washout, and aspirin to prevent flushing was permitted but was not mandatory common treatment. S01	The care policy in the original comparison is specified. This does not mean that actual concomitant medications, doses or times of addition were the same for every participant.	Trial rules for common care, diabetes-medication adjustment, statins and permitted aspirin use	Distinguish the common care policy from actual medication changes, include that policy in the effect of interest, and examine how departures by arm were handled.
10	Partly verified	Full text not readStored summary read	N10 · Comparative harm: HbA1c increaseAre the actual concomitant-treatment adjustments, adherence, rescue treatment and their analytical handling verified for each arm?Required	The original record states that actual concomitant medications were not identical for everyone and that diabetes-medication adjustment was included in the comparison's care policy for the add-on strategy. The extent of changes by individual and arm, adherence to the target dose and detailed handling of rescue treatment were not verified. S01	Differences in concomitant treatment and permission to adjust treatment are verified, but the detailed data and analytical implications were not sufficiently verified.	Histories of changes to diabetes medications, statins and aspirin by arm, together with adherence, rescue-treatment and information on how these were handled in the analysis	Compare actual treatment changes with the effect of interest for the add-on strategy, and examine how departures and adjustments by arm were handled in the analysis.
11	Partly verified	Full text not readStored summary read	N11 · Comparative harm: HbA1c increaseAre the actual methods for randomization, allocation concealment and baseline balance verified?Required; interpretation of comparative harm	ADVENT is a randomized, double-blind, matching-placebo-controlled parallel-group trial. Details of sequence generation and allocation concealment are recorded as unverified. S01	The design and reports of randomization/blinding are verified, but methodological details are lacking. Do not reuse the original B2 as a new bias judgment.	The original randomization-sequence and allocation-concealment procedures, and the baseline-characteristics table by arm	Compare the allocation process with actual baseline balance, distinguishing verified methods from remaining gaps.
12	Met	Full text not readStored summary read	N12 · Comparative harm: HbA1c increaseAre the definition, units, analysis time point and endpoint hierarchy for HbA1c verified?Required	HbA1c is the original trial's primary (1st) safety endpoint and the current page's sole priority outcome. The outcome of interest is the between-group difference in change from baseline to week 16, in %p. S01	The endpoint, hierarchy, time point and measure are verified in the retained original text. This status does not verify prospective agreement with the registration/SAP or an increase in clinical events.	Material on the HbA1c outcome definition, units, time point and endpoint hierarchy, and their correspondence with the original plan	Compare the selected outcome's change, between-group direction and hierarchy with the original results, and consider other endpoints separately.
13	Met	Full text not readStored summary read	N13 · Comparative harm: HbA1c increaseAre the actual laboratory measuring HbA1c and the scheduled visit times verified?Required	HbA1c was scheduled to be assessed at the central laboratory at baseline and weeks 4·8·12·16. The denominators for actual completed measurements at each time point are unverified. S01	The criterion for verifying the laboratory and schedule is met. This is not extended to verification of analysis denominators, assay standardization or handling of missing data.	The original testing schedule, laboratory and participant-specific records of completed measurements	Link scheduled measurements with actual completion records and examine the denominator at each time point.
14	Unverified	Full text not readStored summary read	N14 · Comparative harm: HbA1c increaseAre the HbA1c assay method, equipment, standardization and interference assessment verified?Required	Beyond the information that a central laboratory was used, the exact HbA1c assay method, equipment, standardization and assay-interference assessment are unverified. S01	Detailed specifications needed to compare the selected HbA1c difference with measurement conditions have not been obtained.	Specifications for the central laboratory's HbA1c method, equipment, standardization, quality control and interference assessment	Compare assay conditions with collection at each time point, and examine whether evidence of measurement differences or interference actually exists.
15	Met	Full text not readStored summary read	N15 · Comparative harm: HbA1c increaseAre the overall assigned/treated counts and selected-arm counts distinguished from the HbA1c analysis denominator?Required	Overall, 148 participants were randomized; the authors' ITT/treated population, excluding those who received no treatment, comprised 146 participants. The selected-arm counts of 52/49 are not HbA1c analysis denominators. The structured field randomized_arm_counts=[52,49] is also retained under its original name. S01	The retained manuscript clearly distinguishes each stage from the missing analysis n. This does not mean that the endpoint analysis denominator itself has been verified.	An arm-specific flow table for allocation, treatment, completion and endpoint analysis, and the original basis for the labels used	Compare the stage represented by each sample count with the outcome denominator, and record the overall, selected, and analysis populations separately.
16	Unverified	Full text not readStored summary read	N16 · Comparative harm: HbA1c increaseHave the endpoint-specific HbA1c analysis n, handling of missing data, and variance of paired changes been verified?Required	The HbA1c analysis n=[null,null], change SD=[null,null], and SE=null. Endpoint-specific handling of missing data and variance of paired changes are also unverified. S01	The exact outcome denominators, missing-data information, and paired variances have not been obtained. The counts 52/49, 146, and 148 do not replace them.	Endpoint-specific n by arm, reasons for and handling of missing data, individual repeated measurements, and change-variance data	Compare the analysis populations, missing data at each time point, and variance of paired changes with the original results tables; do not fill unverified information through calculation.
17	Partly verified	Full text not readStored summary read	N17 · Comparative harm: HbA1c increaseHave losses to follow-up, their reasons, and their effects on the endpoint been verified for the selected comparison?Required	The original bias record retains attrition of 17/101=16.83% for the selected comparison. Detailed links between reasons/timing by arm and HbA1c missingness/handling are unverified. S01	Historical attrition figures are available, but endpoint missingness and analytical impact have not been verified. The existing B2 is not used as a score for the new review status.	A table linking reasons and timing of attrition/discontinuation by arm with HbA1c missingness and its handling	Track treatment discontinuation, loss to follow-up, and missing measurements separately to assess which data remain for the selected outcome.
18	Partly verified	Full text not readStored summary read	N18 · Comparative harm: HbA1c increaseDoes the authors' ITT designation agree with the actual effect of interest and analysis population?Required	The authors describe the 146 treated participants as ITT but excluded participants who received no treatment. The selected HbA1c analysis n and exact model are unverified. The comparison is read as an add-on strategy under adjustable diabetes care. S01	The designation and exclusion of untreated participants are verified, but agreement with ITT based on all assigned participants and a formal between-group model cannot be established.	Analysis plan, inclusion/exclusion rules, between-group model, and definition of the effect of interest	Compare the authors' designation with the actual analysis population to distinguish the add-on strategy's effect of interest, adherence effects, and the effects of exclusions.
19	Met	Full text not readStored summary read	N19 · Comparative harm: HbA1c increaseHas attribution of the reported arm-specific HbA1c changes, P value, and existing arithmetic difference been verified?Required	The arm-specific mean changes are +0.29 versus −0.02 %p, and the reported between-group P=0.048. The existing arithmetic difference of +0.31 %p remains designated reported_arm_changes_arithmetic_only; it is not a formal adjusted-model estimate. S01	The sources and analytical nature of the reported values and existing arithmetic value are verified. This is not verification of the magnitude of clinical risk or a formal CI.	Arm-specific mean changes, the reported between-group test, a formal model-estimate table, and the original arithmetic record	Link reported values to outcomes, time points, and analyses, distinguishing descriptive arithmetic from formal estimates without repeating the calculation.
20	Unverified	Full text not readStored summary read	N20 · Comparative harm: HbA1c increaseHave the formal between-group HbA1c change estimate, SE, and CI been verified?Required	The interval field and the standard error field (standard_error) in the retained calculation are null. A confidence interval for the formal between-group change estimate could not be verified from the original data, and +0.31 %p is only an arithmetic difference. S01	The estimate, interval, and variance for the formal change contrast cannot be verified. Do not fill them in from the reported P value alone.	A formal between-group change-estimate table, model, paired variance, denominator, and confidence interval	Link the formal estimate and interval to the verified analysis to examine compatible magnitudes, leaving unverified information unverified.
21	Unverified	Full text not readStored summary read	N21 · Comparative harm: HbA1c increaseHave the matching prospective registration, protocol, SAP, and handling of multiplicity been verified?Required	The matching registration number, original protocol, and analysis plan are unverified, and registration_id and S01 nct are null. The exact multiplicity adjustment for the selected comparison has also not been verified. S01	Insufficient material is available to verify comparison with the prospective plan and the handling of multiplicity. This does not mean that absence of registration or actual selective reporting has been established.	The matching ADVENT registration, original protocol, SAP, and information on analysis changes/multiplicity	Compare the prospective plan with the results by endpoint, time point, and analysis, leaving unobtained information unverified.
22	Unverified	Full text not readStored summary read	N22 · Comparative harm: HbA1c increaseHas a validated threshold for the clinical importance of this HbA1c difference been identified?Required; interpretation of magnitude	An increase signal exists, but its clinical magnitude could not be judged because a validated clinical-importance threshold, variance of paired changes, and formal interval are unavailable. The original EX means that clinical magnitude remains undetermined. S01	A justified importance threshold and corresponding statistical information are lacking. The original P value and arithmetic +0.31 %p alone do not establish the magnitude of important harm.	A validated importance threshold, paired variance, and patient-importance information for this HbA1c comparison	Interpret verified evidence on importance against the formal change estimate/interval; do not replace an importance threshold with conventional significance alone.
23	Partly verified	Full text not readStored summary read	N23 · Comparative harm: HbA1c increaseFor the 1,000 mg arm in the same ADVENT trial, have the HbA1c difference and uncertainty been verified?Supplementary; required for interpreting dose-related/opposing findings	The 1,000 mg/day arm in the same ADVENT trial did not establish a significant difference from placebo, with P=0.16. It is not counted as independent replication, and the current retained summary lacks the complete difference, denominator, and CI for that comparison. S01	The report of a nonsignificant test is verified, but the full between-group effect magnitude and uncertainty have not been verified.	The 1,000 mg arm's HbA1c results, between-group estimate/interval, and denominator in the same trial	Compare the actual results and analyses by dose, retaining them as context from the same family; do not newly calculate direct dose effects or a harmless-dose threshold.
24	Conflicting information	Full text not readStored summary read	N24 · Comparative harm: HbA1c increaseFor the 1,000 mg arm, does baseline HbA1c agree between the table and abstract?Supplementary; required for verifying a conflict concerning the same fact	For the same 1,000 mg arm, baseline HbA1c is recorded as 7.23% in the table and 7.28% in the abstract; it was not arbitrarily corrected. S01	Reports of the same baseline value actually disagree. Successful preservation of the conflict is distinguished from verification of data consistency.	The corresponding value in the original Table 1 and abstract, and any correction or author explanation	Compare the original locations for the same fact side by side; resolve differences only when correction evidence is available, retaining the previous values.
25	Unverified	Full text not readStored summary read	N25 · Comparative harm: HbA1c increaseHas the original material for the no-change conference presentation cited by the study report been verified?Supplementary; required for interpreting replication/opposing evidence	The original study report states that a conference presentation found no HbA1c change. That original presentation could not be directly verified, and the 13 bibliographic records (citation) do not contain a separate presentation identity. S01	The included document contains a secondhand citation, but the actual material, family, and results of the original presentation have not been verified.	The original conference abstract, presentation identity, population/intervention, results, and trial-linkage information	Verify the relationship between the original presentation and study report to distinguish same-family, different-family, and unknown relationships; do not count a secondhand citation as independent replication.
26	Partly verified	Full text not readStored summary read	N26 · Comparative harm: HbA1c increaseHave the actual formulation, comparison, timing, and between-group HbA1c results of ADMIT been verified?Supplementary; required for interpreting indirect/opposing comparisons	ADMIT compares a different IR Niacor formulation, dose, run-in, factorial co-interventions, and population/time-specific effect of interest. HbA1c was maintained within the nicotinic acid arm, while it declined in the placebo arm. The original record also preserves an abstract/table P-value discrepancy, but the current retained summary does not contain the specific figures. S02	The direction and design differences of the indirect comparison are verified, but the complete between-group estimate, denominator, uncertainty, and details of the P-value conflict are lacking.	ADMIT treatment/run-in, factorial co-interventions, diabetic-subgroup results tables, denominators, tests/intervals, and corrections	Compare formulation, population, co-interventions, and the effect of interest over time to distinguish within-arm from between-arm results; do not count them together as direct ER comparisons.
27	Partly verified	Full text not readStored summary read	N27 · Comparative harm: HbA1c increaseHave the actual release formulation, measurements, and period-specific contrasts in the Garg crossover trial been verified?Supplementary; required for interpreting indirect evidence	The PubMed abstract record describes a 13-participant crossover trial, 1 dose of 1.5 g taken three times daily, 8 weeks per period, and a relative increase in glycosylated hemoglobin. The release formulation and equivalence to the selected HbA1c assay are unverified. S03	Abstract-level information on design, administration, and direction is available, but the formulation, assay equivalence, and complete paired analysis have not been verified.	The product release formulation, assay method, crossover sequence/periods, paired results, and denominators in the original Garg full text	Examine the actual periods and paired contrasts in the crossover design and assay equivalence; do not calculate an independent-arm effect.
28	Partly verified	Full text not readStored summary read	N28 · Comparative harm: HbA1c increaseHave the ingredient, product, and comparison in the report of improvement with low-dose niacin and sitagliptin been verified?Supplementary; required for determining the applicability of opposing evidence	The study of low-dose niacin 14 mg/day combined with sitagliptin reported improvement. The exact nicotinic acid/amide identity and product, including its release formulation, are unverified, and this differs from the NIASPAN ER 1,500 mg/day comparison. S04	The favorable direction and the difference in low-dose co-treatment are verified, but the actual ingredient, product, and complete comparative estimate have not been sufficiently verified.	Ingredient/product specifications, sitagliptin/chromium arm composition, comparator, and HbA1c results tables for the Karim trial	Compare the molecule, product, co-treatment, comparator, and direction of results, preserving them separately from the selected comparison.
29	Unverified	Full text not readStored summary read	N29 · Comparative harm: HbA1c increaseHas evidence of independent replication of the exact NIASPAN comparison been verified?Supplementary; required for interpreting replication/generalizability	The direct core evidence (evidence_core) consists only of ADVENT-2002. Other doses, abstracts/secondhand citations, and regulatory summaries from the same trial are not independent replication, and independent replication of the exact comparison was not verified in the current retained material. S01	No material is available to verify independent replication of the exact comparison. Do not turn the 13 bibliographic records (citation) or reports from the same family into a replication count.	Links between unique trials and reports, and independent results tables, for the exact comparison	Link reports to trial families, endpoints, and analyses to distinguish same, different, and unknown relationships; leave the undetermined number of unique studies without a value.
30	Met	Full text not readStored summary read	N30 · Comparative harm: HbA1c increaseHave funding, manufacturer-affiliated authors, and disclosed conflicts of interest in the direct trial been verified?Supplementary; required for interpreting independence	ADVENT records Kos support, manufacturer-affiliated authors, and disclosed speaking/stock relationships. The original I0 is this historical classification and is not used as a new deduction under the criteria. S01	The reported funding and author relationships in the direct trial are verified. This does not mean that independent replication has been verified or the actual magnitude of bias has been calculated.	Original funding information, author affiliations, product supply, speaking/stock/employment relationships, and COI disclosures	Distinguish and verify each source of funding, employment relationship, and disclosure, and examine the scope of claims of independence.
31	Met	Full text not readStored summary read	N31 · Comparative harm: HbA1c increaseCan the products and versions in the official ER documents, and their differences from the historical trial, be verified?Supplementary; required for interpreting official safety information	S05 is the AvPAK/AvKARE generic niacin ER label updated 2026-02-25 and revised 2/2026. S06 reuses the historical file of the 2020 NIASPAN PDF. Neither substitutes for evidence of the original trial's manufacturing batch, titration schedule, or HbA1c effect. S05 S06	The distinctions among products, versions, and roles in the retained bibliography and records are verified. This does not verify current web responses or currency as of 2026-10-05.	Products, versions, dates, description/warning sections in the DailyMed/FDA documents, and information linking them to the trial product	Compare official documents by version, product, and date to distinguish exposure in the historical trial from the safety background.
32	Partly verified	Full text not readStored summary read	N32 · Comparative harm: HbA1c increaseCan the collection of other harms, discontinuations, and exposure denominators in the same trial be verified?Supplementary; required for interpreting overall safety	The original safety wording states that failure to detect major liver or muscle events in the short trial does not guarantee long-term safety. Official ER warnings cover glucose, liver, urate/gout, flushing, and muscle harms with statin co-treatment. The current retained summary does not contain complete information on collection of other AEs or group-specific events/denominators in the selected trial. S01 S05 S06	The retained warnings and limited short-term observations are verified, but complete group-specific AE collection, denominators, and discontinuations have not been verified.	Trial AE definitions, collection procedures, group-specific exposure/events/discontinuations, duration data, and original locations of official warnings	Distinguish continuous HbA1c changes from separate AEs when comparing collection, exposure denominators, and person/event counts; do not fill unreported information with 0.
33	Unverified	Full text not readStored summary read	N33 · Comparative harm: HbA1c increaseCan data on persistent HbA1c effects, long-term complications, and rare harms be verified?Supplementary; required for an extension to long-term/overall safety	Long-term follow-up for the selected question has no value (null), and the original list of unverified matters (unknowns) states that the short-term design cannot determine the magnitude of persistent HbA1c effects, long-term complications, or rare harms. S01	The core design did not investigate the long-term scope, and no verified data are available. This is neither a reason to delete the selected 16-week result nor a claim that no studies exist worldwide.	Exposure/follow-up data on HbA1c after discontinuation, long-term complications, rare events, and vulnerable groups	Distinguish long-term follow-up, repeated-measurement, and event-collection methods suited to the question; do not interpret short-term nondetection as long-term safety.
34	Partly verified	Full text not readStored summary read	N34 · Comparative harm: HbA1c increaseCan the body text, results, and correspondence to ADVENT of the registry leads be verified?Supplementary; required for interpreting registrations/unpublished results	DRKS concerns a different intestinal-release product in healthy/prediabetic participants, and its HbA1c screening range is not a result. Historical access to the official NCT00108485 body text yielded a JS shell/API failure, with only a termination lead from a mirror available. The official NCT06378125 body text also yielded only a shell historically, and its cross-link to DRKS is unverified. S07 S08 S09 S10	Some registry identities, different populations/products, and historical access limits are verified, but official results, reasons for termination, and correspondence among registrations have not been verified.	Official body text/history, results, and verified linkage data for DRKS00030865, NCT00108485, and NCT06378125	Compare each registration's population, release product, endpoints, results, and links to distinguish plans/status/mirror leads from clinical results.
35	Partly verified	Full text not readStored summary read	N35 · Comparative harm: HbA1c increaseCan the actual body text, scope, and family relationships of the review, protocol, and expression-of-concern notice be verified?Supplementary; required for interpreting indirect evidence/editorial history	S11 was used only for discovery/cross-checking through bibliographic records and access-failure records; no pooled figures were adopted. S12 is an indexed protocol, not results. S13 is an indexed lead concerning that protocol; its body text and precise scope could not be read. This lead was not used as evidence against ADVENT. S11 S12 S13	Document types and linkage leads are available, but the actual details of the review content, protocol, and notice text have not been verified.	The review's included trials/results tables, protocol body text, content/scope of the expression-of-concern notice, and document links	Distinguish results, plans, and editorial notices, attributing them only to the corresponding documents; do not count them as independent trials or extend them to unrelated trials.
36	Unverified	Full text not readStored summary read	N36 · Comparative harm: HbA1c increaseDoes this HbA1c comparison also answer questions about incident diabetes or cardiovascular/complication events?Supplementary; required for an extension to clinical events	Fasting glucose, incident diabetes, lipids, FMD, and cardiovascular events are not substitute endpoints for the selected HbA1c success criterion. The current HbA1c increase does not establish differences in long-term complications or cardiovascular events. S01	The selected material addresses the HbA1c comparison; this table has no material for verifying direct estimates of those clinical events.	Definitions, denominators, follow-up, and between-group results for incident diabetes and cardiovascular/complication events in the selected comparison	Review appropriate follow-up that measures and analyzes HbA1c and event endpoints separately, and do not estimate event effects from the surrogate alone.
37	Met	Full text not readStored summary read	N37 · Comparative harm: HbA1c increaseAre current summary reading, each material's historical access/access date, and current external nonreading distinguished?Required	In this review, the complete KO/EN text, evidence, and bibliography in the current retained source summary were read. The 13 bibliographic records (citation) have access_date=2026-09-15 and different historical access levels. Access to all current external papers, labels, registrations, and mirrors was unattempted, and they were unread; the older separate original sources/trial_families files were not read either. S01 S02 S03 S04 S05 S06 S07 S08 S09 S10 S11 S12 S13	The narrow condition of separately recording current local reading and the actual bibliographic records' (citation) historical access/access dates is verified. This does not mean current verification of external full texts.	Actual access, acquisition, and reading events for each material, original locations and dates, and hashes of the retained inputs	Review actions for each material by event/date, and add an actual new external-reading event only when that reading is authorized.
38	Met	Full text not readStored summary read	N38 · Comparative harm: HbA1c increaseAre the original C46, 7 axes, document quality, and new condition statuses distinguished in what they describe?Required	The original clinical-harm claim is rated C, 46, with B/S/R1/I0/EX/B2/CX. This is the evidence tier for the increase claim, not risk magnitude, individual response, safety, or document quality. Document-quality grade A (document_quality) is a single-assistant self-review, not external independent certification. S01	The original assessment and what each designation means are verified and preserved in the complete manuscript. This does not issue a new score, grade, risk rate, or declaration that the conditions are sufficient.	Original records of the assessment, axes, score meaning, document quality, and version	If a correction becomes necessary, preserve the original event and before/after values, and review criterion revision and changes to the clinical assessment as separate tasks.
39	Met	Full text not readStored summary read	N39 · Comparative harm: HbA1c increaseAre the current verification scope, evidence reference date, original server metadata, and update events stated?Required	The original reference date/verification date (verified_date) is 2026-09-15, and the current review date is 2026-10-05. The first-publication date denotes the original editorial issue date, while the deployment timestamp (deployed_at) has no value (null). Update triggers, including matching full texts, plans, corrections, and numerical/classification errors, are retained.	Records of dates, scope, server-metadata meaning, and update conditions are distinguished from the actual original values. This does not mean that a current comprehensive literature search or public release was performed.	Evidence/review dates, actual retained search/selection records, versions, and update/correction events	If authorized new materials become available, compare their identities, dates, original locations, and access levels, and review the linked conditions' observations and status reasons again.

No items match your search or filter.

39 itemsWhat the statuses mean

Assessment scope

Stored-material review date: 2026-10-05
Original evidence date: 2026-09-15
Scope actually checked: Retained Korean and English manuscripts and case-specific criteria and application records. Full papers, supplements, registrations, plans and original data were not read.
What the dates mean: This is the date on which the retained materials were checked, not the date of a search for the latest clinical literature.
Population: Age 21 or older, with stable type 2 diabetes and dyslipidemia; HbA1c ≤9%, fasting glucose ≤200 mg/dL; deficiency status unverified
Ingredient, formulation and route: NIASPAN (Kos) single-ingredient extended-release (ER) oral tablets; separate salt designation, batch and excipients unverified
Dose: Target of 1500 mg/day at bedtime; titration through 375→500→750→1000 mg/day, followed by 1500 mg/day
Comparator: Addition of matching placebo; common policy for diet and adjustable diabetes medication; existing statin users continued treatment, without statins being common treatment for everyone
Measured outcome: Between-group difference in change from baseline to week 16 in HbA1c (%p); the trial's primary (1st) safety endpoint
Duration: Total of 16 weeks, including 4 weeks of titration; target dose during weeks 5–16
Questions outside this scope: Do not extend this to reduced efficacy, a general safety-only flag (safety_only), all niacin formulations, FPG/incident diabetes/lipids/FMD/cardiovascular events, long-term complications, individual risk rates or an optimal dose.

Evidence and sources

The links below lead to the sources. A link alone does not mean the original source was read or its latest publication status verified.

S01 · Grundy SM et al. ADVENT: Efficacy, Safety, and Tolerability of Once-Daily Niacin for the Treatment of Dyslipidemia Associated With Type 2 Diabetes. Arch Intern Med. 2002;162:1568–1576.

Source

Material type: Publisher's original article in full-text HTML, with tables/figures (historically read)
Materials actually read: The corresponding Korean and English summaries and bibliographic records in the retained manuscript were read. The linked external original materials were not read in this review.
Findings recorded in the stored summary: Record at the time of preservation: randomized, double-blind, parallel-group ADVENT. Overall, 148 participants were assigned/146 exposed; the selected-arm counts of 52/49 are not HbA1c analysis denominators. Including 4 weeks of titration, the total duration was 16 weeks, with a target of 1,500 mg/day during weeks 5–16. Changes were +0.29 versus −0.02 %p, with existing arithmetic of +0.31 %p and reported P=0.048; the formal change-contrast CI, variance, and endpoint n are unverified. The policy allowed diabetes-drug adjustment, continuation by existing statin users, and permitted/nonmandatory ASA; Kos funding and manufacturer-author/disclosure relationships are recorded. The same trial's 1,000 mg arm P=.16, the baseline 7.23%/7.28% conflict, and the secondhand citation of an unverified original presentation are preserved separately.
Record level: This information is recorded in the retained manuscript. It is not the result of a new comparison with current external original materials.
Study overlap and independent replication: The actual study family recorded in the source's evidence/family_id field. The same trial's 1,000 mg arm and the presentation cited secondhand are not counted as independent replication.

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
Publisher's original article in full-text HTML, with tables/figures (historically read)	Currently unverified	Not attempted in this review	Unread	Historical access date for the material: 2026-09-15; recorded level: full-text HTML. Only the retained summary was read in this review; external access was not attempted, and the material was neither acquired nor read.

S02 · Elam MB et al. Effect of Niacin on Lipid and Lipoprotein Levels and Glycemic Control in Patients With Diabetes and Peripheral Arterial Disease: The ADMIT Study. JAMA. 2000;284:1263–1270.

Source

Material type: Publisher's original article in full-text HTML (historically read)
Materials actually read: The corresponding Korean and English summaries and bibliographic records in the retained manuscript were read. The linked external original materials were not read in this review.
Findings recorded in the stored summary: Record at the time of preservation: ADMIT is a comparison involving IR Niacor, a different dose/run-in, factorial co-treatments, and a population/time-specific effect of interest. Within-group maintenance of HbA1c in the nicotinic-acid arm, while it fell in the placebo arm, differs from a null between-group effect. The abstract/table P discrepancy remains in the original record, but this retained summary contains no specific values.
Record level: This information is recorded in the retained manuscript. It is not the result of a new comparison with current external original materials.
Study overlap and independent replication: ADMIT is named in the original bibliographic citation (cite). It does not replicate the exact ADVENT comparison.

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
Publisher's original article in full-text HTML (historically read)	Currently unverified	Not attempted in this review	Unread	Historical access date for the material: 2026-09-15; recorded level: full-text HTML. Only the retained summary was read in this review; external access was not attempted, and the material was neither acquired nor read.

S03 · Garg A, Grundy SM. Nicotinic acid as therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. JAMA. 1990;264:723–726.

Source

Material type: PubMed bibliographic record/abstract (historically read)
Materials actually read: The corresponding Korean and English summaries and bibliographic records in the retained manuscript were read. The linked external original materials were not read in this review.
Findings recorded in the stored summary: Record at the time of preservation: the abstract record describes a crossover study of 13 participants, 1 dose of 1.5 g taken three times daily, each period lasting 8 weeks, and a relative increase in glycosylated-hemoglobin. The exact release formulation and equivalence to the selected HbA1c assay are unverified. No independent-arm calculation was performed.
Record level: This information is recorded in the retained manuscript. It is not the result of a new comparison with current external original materials.
Study overlap and independent replication: The bibliography identifies a particular crossover study, but no structure linking unique study families is currently available. No new total of families or independent participants is issued.

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
PubMed bibliographic record/abstract (historically read)	Currently unverified	Not attempted in this review	Unread	Historical access date for the material: 2026-09-15; recorded level: abstract. Only the retained summary was read in this review; external access was not attempted, and the material was neither acquired nor read.

S04 · Karim F et al. The therapeutic effectiveness of sitagliptin with niacin and chromium picolinate on glycosylated hemoglobin in type 2 diabetes mellitus patients. Biomed Res Ther. 2018;5(8):2610–2619.

Source

Material type: Publisher's original article in full-text HTML (historically read)
Materials actually read: The corresponding Korean and English summaries and bibliographic records in the retained manuscript were read. The linked external original materials were not read in this review.
Findings recorded in the stored summary: Record at the time of preservation: a study combining low-dose niacin 14 mg/day with sitagliptin reported improvement. The exact nicotinic acid/amide identity and release product are unverified, and this is not a comparison of prescription ER NIASPAN 1,500 mg/day. The chromium co-treatment arm in the methods is also not combined with the selected comparison.
Record level: This information is recorded in the retained manuscript. It is not the result of a new comparison with current external original materials.
Study overlap and independent replication: The bibliography contains an individual clinical study, but its product/co-treatment differs from the selected ER comparison; no new total of unique families is issued.

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
Publisher's original article in full-text HTML (historically read)	Currently unverified	Not attempted in this review	Unread	Historical access date for the material: 2026-09-15; recorded level: full-text HTML. Only the retained summary was read in this review; external access was not attempted, and the material was neither acquired nor read.

S05 · DailyMed: NIACIN extended-release tablets (AvPAK repackaged label; AvKARE adverse-event contact), updated 2026-02-25, revised 2/2026.

Source

Material type: Full online text of the official DailyMed product label (historically read)
Materials actually read: The corresponding Korean and English summaries and bibliographic records in the retained manuscript were read. The linked external original materials were not read in this review.
Findings recorded in the stored summary: Record at the time of preservation: the AvPAK/AvKARE generic niacin ER label updated 2026-02-25 and revised 2/2026. It provides background on glucose, liver, urate/gout, flushing, and muscle harms with statin co-treatment, as well as warnings about formulation substitution/titration. It is not used to impute the original NIASPAN manufacturing details, titration, or HbA1c effect, and its currency was not checked in this review.
Record level: This information is recorded in the retained manuscript. It is not the result of a new comparison with current external original materials.
Study overlap and independent replication: An administrative/official label; no clinical trial family is assigned.

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
Full online text of the official DailyMed product label (historically read)	Currently unverified	Not attempted in this review	Unread	Historical access date for the material: 2026-09-15; recorded level: full-text HTML. Only the retained summary was read in this review; external access was not attempted, and the material was neither acquired nor read.

S06 · FDA: NIASPAN extended-release niacin prescribing information, 2020.

Source

Material type: FDA NIASPAN prescribing-information PDF and warning sections (historically read)
Materials actually read: The corresponding Korean and English summaries and bibliographic records in the retained manuscript were read. The linked external original materials were not read in this review.
Findings recorded in the stored summary: Record at the time of preservation: the historical file of the 2020 NIASPAN prescribing information was reused, and a record states that the PDF warning pages were read. It was not displayed as a new, latest label; S05 serves the role of the safety-document check at the reference date. Product descriptions and liver/glucose/muscle/urate warnings are distinguished from the trial effect.
Record level: This information is recorded in the retained manuscript. It is not the result of a new comparison with current external original materials.
Study overlap and independent replication: An official document; no clinical trial family is assigned.

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
FDA NIASPAN prescribing-information PDF and warning sections (historically read)	Currently unverified	Not attempted in this review	Unread	Historical access date for the material: 2026-09-15; recorded level: full-text document PDF. Only the retained summary was read in this review; external access was not attempted, and the material was neither acquired nor read.

S07 · DRKS00030865: controlled ileocolonic-release nicotinic acid safety/pharmacokinetic study.

Source

Material type: Official DRKS online registry record (historically read)
Materials actually read: The corresponding Korean and English summaries and bibliographic records in the retained manuscript were read. The linked external original materials were not read in this review.
Findings recorded in the stored summary: Record at the time of preservation: a safety/pharmacokinetic study of a different ileocolonic-release nicotinic acid product in healthy/prediabetic participants. The HbA1c screening range is not an efficacy result, and completed status does not prove that HbA1c results are publicly available.
Record level: This information is recorded in the retained manuscript. It is not the result of a new comparison with current external original materials.
Study overlap and independent replication: The DRKS00030865 registry identifier is retained, but it is not counted as a new trial result or replication of ADVENT.

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
Official DRKS online registry record (historically read)	Currently unverified	Not attempted in this review	Unread	Historical access date for the material: 2026-09-15; recorded level: registry body text. Only the retained summary was read in this review; external access was not attempted, and the material was neither acquired nor read.

S08 · ClinicalTrials.gov record NCT00108485.

Source

Material type: Official ClinicalTrials.gov registration page/JS shell (historical failure to access body text)
Materials actually read: The corresponding Korean and English summaries and bibliographic records in the retained manuscript were read. The linked external original materials were not read in this review.
Findings recorded in the stored summary: Record at the time of preservation: the official page was a JS shell at the time, and the API search also failed. Because the original body text/results could not be verified, endpoints, termination reasons, and results were not inferred. No access attempt was made in this review.
Record level: This information is recorded in the retained manuscript. It is not the result of a new comparison with current external original materials.
Study overlap and independent replication: It has the same registration number as S09. This does not verify official results, the reason for termination, correspondence to ADVENT, or a clinical study family.

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
Official ClinicalTrials.gov registration page/JS shell (historical failure to access body text)	Currently unverified	Not attempted in this review	Unread	Historical access date for the material: 2026-09-15; recorded level: historical failure to access body text. Only the retained summary was read in this review; external access was not attempted, and the material was neither acquired nor read.

S09 · Study of the Use of Niaspan for Treatment of Dyslipidemia in Diabetic Nephropathy — registry mirror lead.

Source

Material type: Veeva secondary (2nd-source) registry mirror web record (historically read)
Materials actually read: The corresponding Korean and English summaries and bibliographic records in the retained manuscript were read. The linked external original materials were not read in this review.
Findings recorded in the stored summary: Record at the time of preservation: a lead for a terminated study under NCT00108485 and a link to the official record were found. Mirror information was not elevated to verified clinical results or used for scoring, and the official body text was inaccessible.
Record level: This information is recorded in the retained manuscript. It is not the result of a new comparison with current external original materials.
Study overlap and independent replication: It has the same registry identifier as S08, but the mirror lead is not counted as an independent trial or clinical result.

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
Veeva secondary (2nd-source) registry mirror web record (historically read)	Currently unverified	Not attempted in this review	Unread	Historical access date for the material: 2026-09-15; recorded level: historical secondary (2nd-source) registry mirror. Only the retained summary was read in this review; external access was not attempted, and the material was neither acquired nor read.

S10 · ClinicalTrials.gov NCT06378125: nicotinic-acid intestinal-release study lead.

Source

Material type: Official ClinicalTrials.gov registration page/JS shell (historical failure to access body text)
Materials actually read: The corresponding Korean and English summaries and bibliographic records in the retained manuscript were read. The linked external original materials were not read in this review.
Findings recorded in the stored summary: Record at the time of preservation: only a JS shell was verified on the official NCT06378125 page at the time. No verified link establishing that it was the same registration as DRKS00030865 was obtained, and neither registration was counted as replication of the core comparison.
Record level: This information is recorded in the retained manuscript. It is not the result of a new comparison with current external original materials.
Study overlap and independent replication: Whether NCT06378125 and DRKS00030865 are the same registration remains unverified without a verified cross-link.

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
Official ClinicalTrials.gov registration page/JS shell (historical failure to access body text)	Currently unverified	Not attempted in this review	Unread	Historical access date for the material: 2026-09-15; recorded level: historical failure to access body text. Only the retained summary was read in this review; external access was not attempted, and the material was neither acquired nor read.

S11 · Xiang et al. Effectiveness of niacin supplementation for patients with type 2 diabetes: A meta-analysis of randomized controlled trials. Medicine. 2020;99:e21235.

Source

Material type: Reference to a PMC review page and indexed bibliography (historical failure to access the full text)
Materials actually read: The corresponding Korean and English summaries and bibliographic records in the retained manuscript were read. The linked external original materials were not read in this review.
Findings recorded in the stored summary: Record at the time of preservation: only the bibliography of the 2020 review was verified; access to the PMC full text encountered a challenge, and the publisher returned HTTP 402. No pooled figures were adopted, and the review was not counted as an independent trial.
Record level: This information is recorded in the retained manuscript. It is not the result of a new comparison with current external original materials.
Study overlap and independent replication: The review is not a new independent human trial. The families and overlap of its included trials are currently unverified.

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
Reference to a PMC review page and indexed bibliography (historical failure to access the full text)	Currently unverified	Not attempted in this review	Unread	Historical access date for the material: 2026-09-15; recorded level: historical bibliographic information/access failure. Only the retained summary was read in this review; external access was not attempted, and the material was neither acquired nor read.

S12 · The efficacy of niacin supplementation in type 2 diabetes patients: Study protocol of a randomized controlled trial.

Source

Material type: Reference to a PMC protocol page and indexed bibliography (historical failure to access the full text)
Materials actually read: The corresponding Korean and English summaries and bibliographic records in the retained manuscript were read. The linked external original materials were not read in this review.
Findings recorded in the stored summary: Record at the time of preservation: the plan's title and identifiers were verified in an index, but full-text access failed. A protocol is not results. There is a link lead to the S13 expression-of-concern notice, but its details were not fully verified, and it was not used as evidence of an ADVENT-related defect.
Record level: This information is recorded in the retained manuscript. It is not the result of a new comparison with current external original materials.
Study overlap and independent replication: A planning document, not human trial results or confirmation of membership in the ADVENT family.

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
Reference to a PMC protocol page and indexed bibliography (historical failure to access the full text)	Currently unverified	Not attempted in this review	Unread	Historical access date for the material: 2026-09-15; recorded level: historical bibliographic information/access failure. Only the retained summary was read in this review; external access was not attempted, and the material was neither acquired nor read.

S13 · Expression of Concern: Study protocols (indexed notice lead, Medicine 2025).

Source

Material type: Publisher's expression-of-concern notice link and indexed bibliography (historical failure to access body text)
Materials actually read: The corresponding Korean and English summaries and bibliographic records in the retained manuscript were read. The linked external original materials were not read in this review.
Findings recorded in the stored summary: Record at the time of preservation: an indexed lead to a 2025 expression-of-concern notice was linked to S12, but the publisher's body text and the precise scope of the notice could not be read. The expmression spelling in the actual returned URL was preserved exactly; the lead was not used as evidence to discredit the independent ADVENT report.
Record level: This information is recorded in the retained manuscript. It is not the result of a new comparison with current external original materials.
Study overlap and independent replication: An editorial notice is not an independent human trial. A lead unrelated to ADVENT is not attributed to the ADVENT harm result.

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
Publisher's expression-of-concern notice link and indexed bibliography (historical failure to access body text)	Currently unverified	Not attempted in this review	Unread	Historical access date for the material: 2026-09-15; recorded level: historical bibliographic information/access failure. Only the retained summary was read in this review; external access was not attempted, and the material was neither acquired nor read.

Report counts versus independent study counts

ADVENT-2002: the 1,000 mg arm and the conference presentation cited secondhand are not counted as separate independent replication. ADMIT: an indirect comparison with a different IR formulation, dose, run-in, population, and time-specific effect of interest. NCT00108485: official shell/secondary (2nd-source) mirror leads for the same registry identifier. Clinical results, correspondence to ADVENT, and the number of unique studies are unverified. The direct exact comparison belongs to the single ADVENT-2002 family. The 13 reports do not mean 13 independent trials; the total numbers of unique trials and participants are unverified.

Review criteria

Version NGM-v3092-NIASPAN-HBA1C-INCREASE-1.0 · Criteria record date 2026-10-05. These are Chamgap's own application conditions, informed by the referenced methods. They do not constitute official assessment-tool certification or a new efficacy score.

N01 · Which population, intervention, comparator, time period and endpoint define the comparative harm claim?

Required materials and conditions: Material linking the identity of the current claim with the actual population, intervention, comparator, endpoint and time point
Conditions for verification: The actual original material specifies the boundaries: stable type 2 diabetes and dyslipidemia, adjustable usual care, NIASPAN ER added versus matching placebo, and change over a total of 16 weeks in HbA1c.
Requirement and applicability: Required
Application exceptions: Do not change the clinical-harm/increase classification (clinical_harm_claim/increase) to reduced efficacy or a safety-only flag (safety_only), or include other niacin interventions or other clinical endpoints.
Why this condition is needed: Needed to distinguish the quantitative harm claim of an HbA1c increase from glycemic-improvement efficacy and a general safety indicator.
Referenced methods: C01: Question-clarification principles in M03 §3.1, §3.2.1–3.2.4; detailed separation rules are internally designed / C04: M03 §3.2.1; detailed population criteria are internally designed / C05: M03 §3.2.2–3.2.3; reverse-direction labeling and test adaptations are internally designed / C06: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are internally designed / H09: Chamgap's own interpretive boundaries. The M19 principles are referenced; no official causality tool was applied. Reason for adapting this to comparative HbA1c harm: needed to distinguish the quantitative harm claim of an HbA1c increase from glycemic-improvement efficacy and a general safety indicator. No new clinical causality/grade judgment or official methodological procedure was performed.

N02 · Are the actual ingredient, product, release formulation and route verified?

Required materials and conditions: The core trial's product name, ingredient, release formulation and route, and the corresponding locations in the official product description
Conditions for verification: The original material distinguishes the single active ingredient nicotinic acid, NIASPAN (Kos), ER oral tablets, and the excluded molecules/formulations.
Requirement and applicability: Required
Application exceptions: Do not resolve an unverified separate salt designation by assuming equivalence to another salt. Distinguish the null value/not_applicable status for plant-part information (botanical_part) from the unverified manufacturing origin.
Why this condition is needed: Needed to avoid transferring results for NIASPAN extended-release nicotinic acid to nicotinamide or IR/SR formulations.
Referenced methods: C05: M03 §3.2.2–3.2.3; reverse-direction labeling and test adaptations are internally designed / H03: M19 §19.2.2–19.2.4, M03 §3.2.3; internal application. Reason for adapting this to comparative HbA1c harm: needed to avoid transferring results for NIASPAN extended-release nicotinic acid to nicotinamide or IR/SR formulations. No new clinical causality/grade judgment or official methodological procedure was performed.

N03 · Is the actual information on manufacturing origin, batch and excipients verified?

Required materials and conditions: Specifications for the trial product's manufacturing process, raw-material origin, batch and excipients
Conditions for verification: Direct material is available to verify the selected product's manufacturing origin, batch and excipients.
Requirement and applicability: Supplementary; required for detailed product identity
Application exceptions: Although plant-part information is not applicable to this chemical ingredient, do not change the unverified/null manufacturing origin to Not applicable.
Why this condition is needed: Knowing a product name and knowing its actual manufacturing origin, batch and excipients are different levels of information.
Referenced methods: C05: M03 §3.2.2–3.2.3; reverse-direction labeling and test adaptations are internally designed. Reason for adapting this to comparative HbA1c harm: knowing a product name and knowing its actual manufacturing origin, batch and excipients are different levels of information. No new clinical causality/grade judgment or official methodological procedure was performed.

N04 · Are the trial's diagnosis, stability, age and inclusion/exclusion criteria verified?

Required materials and conditions: Inclusion/exclusion criteria, diagnosis, baseline-characteristics table and material verifying stability
Conditions for verification: The original material specifies age 21 or older, stable type 2 diabetes and dyslipidemia, diagnoses, entry criteria, sex and major exclusions.
Requirement and applicability: Required
Application exceptions: Keep participants' baseline niacin-deficiency status separately unverified, and do not invent detailed subgroup effects.
Why this condition is needed: Needed to avoid applying the selected trial's results unchanged to people with diabetes generally or to healthy people.
Referenced methods: C04: M03 §3.2.1; detailed population criteria are internally designed / H05: Design considerations in M19 §19.2.2–19.2.4; detailed recording of confounding is internally designed. Reason for adapting this to comparative HbA1c harm: needed to avoid applying the selected trial's results unchanged to people with diabetes generally or to healthy people. No new clinical causality/grade judgment or official methodological procedure was performed.

N05 · Are baseline niacin status, deficiency classification and total dietary intake verified?

Required materials and conditions: Baseline niacin measurements, deficiency-classification criteria and data on total dietary niacin
Conditions for verification: Participant-specific data are available on baseline niacin measurement, deficiency classification and total dietary intake.
Requirement and applicability: Supplementary; required for interpreting deficiency/total exposure
Application exceptions: Do not extend information not identified in the text accessed at the time into a claim that it was unreported throughout the entire paper, or into evidence that deficiency was absent.
Why this condition is needed: Needed to avoid treating deficiency correction and prescription-drug addition in nondeficient participants as the same question.
Referenced methods: C04: M03 §3.2.1; detailed population criteria are internally designed / H05: Design considerations in M19 §19.2.2–19.2.4; detailed recording of confounding is internally designed. Reason for adapting this to comparative HbA1c harm: needed to avoid treating deficiency correction and prescription-drug addition in nondeficient participants as the same question. No new clinical causality/grade judgment or official methodological procedure was performed.

N06 · Are the actual planned titration, target dose and dosing frequency verified?

Required materials and conditions: Trial treatment schedule, target dose, tablet count and data on actual adherence/dose reached
Conditions for verification: Bedtime administration at 1 dose per 1 day, weekly titration, target dose and tablet count are linked to the actual plan.
Requirement and applicability: Required
Application exceptions: The study schedule is not a personal dosing instruction, and actual adherence/doses reached are distinguished from the planned titration schedule.
Why this condition is needed: Needed to avoid displaying the target dose as a fixed dose actually taken throughout the entire period.
Referenced methods: C05: M03 §3.2.2–3.2.3; reverse-direction labeling and test adaptations are internally designed / H02: Design-specific harm questions in M19 §19.2; details of temporal relationships are internally designed. Reason for adapting this to comparative HbA1c harm: needed to avoid displaying the target dose as a fixed dose actually taken throughout the entire period. No new clinical causality/grade judgment or official methodological procedure was performed.

N07 · Are the titration period, target-dose period and total follow-up period separately identified and verified?

Required materials and conditions: Schedules for treatment, titration, target-dose maintenance and end of follow-up, together with long-term follow-up material
Conditions for verification: The planned total of 16 weeks, 4 weeks of titration and target dose in weeks 5–16 are distinguished from the absence of long-term follow-up.
Requirement and applicability: Required
Application exceptions: Do not use the planned 12-week target-dose period as a new clinical minimum duration or long-term safety criterion.
Why this condition is needed: Needed to avoid turning the total of 16 weeks into fixed exposure to the target of 1,500 mg/day for 16 weeks, or into long-term follow-up.
Referenced methods: C06: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are internally designed / H02: Design-specific harm questions in M19 §19.2; details of temporal relationships are internally designed / H08: M19 §19.1.2–19.2.4; internal application. Reason for adapting this to comparative HbA1c harm: needed to avoid turning the total of 16 weeks into fixed exposure to the target of 1,500 mg/day for 16 weeks, or into long-term follow-up. No new clinical causality/grade judgment or official methodological procedure was performed.

N08 · Is the actual composition of the matching placebo verified?

Required materials and conditions: Material on placebo manufacture, composition, appearance, corresponding tablets and blinding assessment
Conditions for verification: The matching placebo and a direct description of its composition, appearance and whether it contained active ingredients are verified.
Requirement and applicability: Required
Application exceptions: Do not use unverified placebo details as evidence that there was no placebo or as confirmation that blinding failed.
Why this condition is needed: Needed to avoid turning the term matching placebo into verification of its exact ingredients or complete blinding.
Referenced methods: C05: M03 §3.2.2–3.2.3; reverse-direction labeling and test adaptations are internally designed / H03: M19 §19.2.2–19.2.4, M03 §3.2.3; internal application / E02: M03 §3.2.3, M08 §8.2.2–8.2.3; internal application. Reason for adapting this to comparative HbA1c harm: needed to avoid turning the term matching placebo into verification of its exact ingredients or complete blinding. No new clinical causality/grade judgment or official methodological procedure was performed.

N09 · Are the common policies on diabetes-treatment adjustment, statins and aspirin verified?

Required materials and conditions: Trial rules for common care, diabetes-medication adjustment, statins and permitted aspirin use
Conditions for verification: Permission to change usual diabetes care, continuation of existing statins, the absence of a statin requirement for everyone, and the policy permitting but not requiring aspirin are verified.
Requirement and applicability: Required
Application exceptions: Do not automatically judge diabetes-medication adjustment as contamination or design failure; preserve it as the care policy in the comparison of this add-on strategy.
Why this condition is needed: Needed to distinguish a common policy from a claim that everyone actually received identical concomitant medication.
Referenced methods: C05: M03 §3.2.2–3.2.3; reverse-direction labeling and test adaptations are internally designed / H03: M19 §19.2.2–19.2.4, M03 §3.2.3; internal application / H05: Design considerations in M19 §19.2.2–19.2.4; detailed recording of confounding is internally designed / E02: M03 §3.2.3, M08 §8.2.2–8.2.3; internal application. Reason for adapting this to comparative HbA1c harm: needed to distinguish a common policy from a claim that everyone actually received identical concomitant medication. No new clinical causality/grade judgment or official methodological procedure was performed.

N10 · Are the actual concomitant-treatment adjustments, adherence, rescue treatment and their analytical handling verified for each arm?

Required materials and conditions: Histories of changes to diabetes medications, statins and aspirin by arm, together with adherence, rescue-treatment and information on how these were handled in the analysis
Conditions for verification: Actual data verify concomitant-medication changes, attainment of the target dose, adherence/discontinuation and the corresponding analytical handling for each arm.
Requirement and applicability: Required
Application exceptions: The existence of a policy permitting changes does not establish that the extent of changes by arm, adherence or the adjustment model was also verified.
Why this condition is needed: Needed to avoid turning the observed add-on strategy into an isolated drug contribution under completely fixed diabetes medication.
Referenced methods: H05: Design considerations in M19 §19.2.2–19.2.4; detailed recording of confounding is internally designed / E02: M03 §3.2.3, M08 §8.2.2–8.2.3; internal application / E04: M08 §8.2.2, M15 §15.3.1; internal application. Reason for adapting this to comparative HbA1c harm: needed to avoid turning the observed add-on strategy into an isolated drug contribution under completely fixed diabetes medication. No new clinical causality/grade judgment or official methodological procedure was performed.

N11 · Are the actual methods for randomization, allocation concealment and baseline balance verified?

Required materials and conditions: The original randomization-sequence and allocation-concealment procedures, and the baseline-characteristics table by arm
Conditions for verification: Material is available to verify the parallel-group design, random-sequence generation, allocation concealment and baseline balance.
Requirement and applicability: Required; interpretation of comparative harm
Application exceptions: Do not turn unverified concealment into actual absence of concealment or a confirmed bias defect. No new RoB grade is issued.
Why this condition is needed: The labels RCT and double-blind alone cannot establish that sequence generation, concealment and selection differences have been addressed.
Referenced methods: E01: M08 §8.1–8.2.3; internal application / H05: Design considerations in M19 §19.2.2–19.2.4; detailed recording of confounding is internally designed. Reason for adapting this to comparative HbA1c harm: the labels RCT and double-blind alone cannot establish that sequence generation, concealment and selection differences have been addressed. No new clinical causality/grade judgment or official methodological procedure was performed.

N12 · Are the definition, units, analysis time point and endpoint hierarchy for HbA1c verified?

Required materials and conditions: Material on the HbA1c outcome definition, units, time point and endpoint hierarchy, and their correspondence with the original plan
Conditions for verification: The between-group difference in change from baseline to week 16 in HbA1c, the %p unit, and its status as the original trial's primary (1st) safety endpoint are distinguished.
Requirement and applicability: Required
Application exceptions: Keep the reported primary (1st) hierarchy separate from whether its prospective registration plan has been verified.
Why this condition is needed: Needed to avoid reading the primary (1st) safety endpoint, HbA1c, as a secondary lipid result, diagnostic event or incidence rate.
Referenced methods: C06: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are internally designed / H01: M19 §19.1.2–19.2.4; detailed distinctions are internally designed / E03: M08 Table 8.2.a, M03 §3.2.4; internal application / E06: M08 Table 8.2.a, M04 §4.6.3; internal application. Reason for adapting this to comparative HbA1c harm: needed to avoid reading the primary (1st) safety endpoint, HbA1c, as a secondary lipid result, diagnostic event or incidence rate. No new clinical causality/grade judgment or official methodological procedure was performed.

N13 · Are the actual laboratory measuring HbA1c and the scheduled visit times verified?

Required materials and conditions: The original testing schedule, laboratory and participant-specific records of completed measurements
Conditions for verification: The original material specifies the central laboratory and measurements at baseline and weeks 4·8·12·16.
Requirement and applicability: Required
Application exceptions: Do not turn scheduled measurement times into a claim that completion/analysis data for every participant have been obtained.
Why this condition is needed: Needed to distinguish repeated measurement time points from the single end-of-study outcome and clarify which follow-up period the result belongs to.
Referenced methods: C06: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are internally designed / H01: M19 §19.1.2–19.2.4; detailed distinctions are internally designed / H02: Design-specific harm questions in M19 §19.2; details of temporal relationships are internally designed / E03: M08 Table 8.2.a, M03 §3.2.4; internal application. Reason for adapting this to comparative HbA1c harm: needed to distinguish repeated measurement time points from the single end-of-study outcome and clarify which follow-up period the result belongs to. No new clinical causality/grade judgment or official methodological procedure was performed.

N14 · Are the HbA1c assay method, equipment, standardization and interference assessment verified?

Required materials and conditions: Specifications for the central laboratory's HbA1c method, equipment, standardization, quality control and interference assessment
Conditions for verification: Material is available to verify the exact HbA1c method, equipment and standardization, and interference/measurement limitations by arm.
Requirement and applicability: Required
Application exceptions: Do not turn unverified assay details into invalidity of the entire result or confirmation of assay interference.
Why this condition is needed: The description of a central laboratory alone cannot guarantee measurement standardization or the absence of interference by arm.
Referenced methods: H01: M19 §19.1.2–19.2.4; detailed distinctions are internally designed / E03: M08 Table 8.2.a, M03 §3.2.4; internal application. Reason for adapting this to comparative HbA1c harm: the description of a central laboratory alone cannot guarantee measurement standardization or the absence of interference by arm. No new clinical causality/grade judgment or official methodological procedure was performed.

N15 · Are the overall assigned/treated counts and selected-arm counts distinguished from the HbA1c analysis denominator?

Required materials and conditions: An arm-specific flow table for allocation, treatment, completion and endpoint analysis, and the original basis for the labels used
Conditions for verification: The overall counts of 148 assigned and 146 treated participants, the selected-arm counts of 52/49, and the unverified endpoint-specific analysis n are each explicitly distinguished.
Requirement and applicability: Required
Application exceptions: Preserve the original bytes of the structured group-count field name randomized_arm_counts and the manuscript's description of the treated groups; do not reinterpret them as the actual endpoint analysis n.
Why this condition is needed: Needed to avoid substituting the overall sample or treated-arm counts for the analysis denominator of the selected HbA1c outcome.
Referenced methods: C07: M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; adaptations for specific designs were developed internally / H06: M19 §19.1.2–19.2.4, M04 §4.6.3; internal application / E04: M08 §8.2.2, M15 §15.3.1; internal application. Reason for adapting this to the comparative HbA1c harm question: This is needed to avoid substituting the overall sample or treated-arm counts for the analysis denominator of the selected HbA1c outcome. No new clinical causality/grade judgment was made, and no official methodology was applied.

N16 · Have the endpoint-specific HbA1c analysis n, handling of missing data, and variance of paired changes been verified?

Required materials and conditions: Endpoint-specific n by arm, reasons for and handling of missing data, individual repeated measurements, and change-variance data
Conditions for verification: The HbA1c analysis n, handling of missing data, and SD/SE of paired changes for the selected comparison are linked to original data.
Requirement and applicability: Required
Application exceptions: Preserve the original missing values. Do not substitute arm-specific end-of-study SEs for change SD/SE or perform new calculations.
Why this condition is needed: This is needed to avoid filling in analysis denominators, variances, or intervals from the selected-arm counts of 52/49 and a rounded P value.
Referenced methods: C07: M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; adaptations for specific designs were developed internally / H06: M19 §19.1.2–19.2.4, M04 §4.6.3; internal application / E04: M08 §8.2.2, M15 §15.3.1; internal application / E05: M15 §15.3.1–15.3.3; internal application. Reason for adapting this to the comparative HbA1c harm question: This is needed to avoid filling in analysis denominators, variances, or intervals from the selected-arm counts of 52/49 and a rounded P value. No new clinical causality/grade judgment was made, and no official methodology was applied.

N17 · Have losses to follow-up, their reasons, and their effects on the endpoint been verified for the selected comparison?

Required materials and conditions: A table linking reasons and timing of attrition/discontinuation by arm with HbA1c missingness and its handling
Conditions for verification: Attrition counts, reasons by arm, timing, and their links to HbA1c missingness and its analytical impact are verified for the selected comparison.
Requirement and applicability: Required
Application exceptions: The expression 17/101=16.83% is an existing record and is not recalculated. Original scoring criteria such as 15% or 200 participants are not imposed as adequacy criteria for the new conditions.
Why this condition is needed: This is needed to avoid treating reported attrition and HbA1c missingness as the same event, or applying the original historical rate as a new bias score.
Referenced methods: C07: M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; adaptations for specific designs were developed internally / H06: M19 §19.1.2–19.2.4, M04 §4.6.3; internal application. Reason for adapting this to the comparative HbA1c harm question: This is needed to avoid treating reported attrition and HbA1c missingness as the same event, or applying the original historical rate as a new bias score. No new clinical causality/grade judgment was made, and no official methodology was applied.

N18 · Does the authors' ITT designation agree with the actual effect of interest and analysis population?

Required materials and conditions: Analysis plan, inclusion/exclusion rules, between-group model, and definition of the effect of interest
Conditions for verification: Agreement is verified between the effect of assignment overall or the actual effect of interest and the analysis inclusion/exclusion rules and model.
Requirement and applicability: Required
Application exceptions: Retain the authors' ITT wording while distinguishing it from actual exclusions and the effect of interest. Do not infer an adherence effect or an adjusted model.
Why this condition is needed: This is needed to avoid treating a population that excludes untreated participants as ITT based on all randomized participants.
Referenced methods: E04: M08 §8.2.2, M15 §15.3.1; internal application / H03: M19 §19.2.2–19.2.4, M03 §3.2.3; internal application / H06: M19 §19.1.2–19.2.4, M04 §4.6.3; internal application. Reason for adapting this to the comparative HbA1c harm question: This is needed to avoid treating a population that excludes untreated participants as ITT based on all randomized participants. No new clinical causality/grade judgment was made, and no official methodology was applied.

N19 · Has attribution of the reported arm-specific HbA1c changes, P value, and existing arithmetic difference been verified?

Required materials and conditions: Arm-specific mean changes, the reported between-group test, a formal model-estimate table, and the original arithmetic record
Conditions for verification: The selected comparison's +0.29 versus −0.02 %p, reported P=.048, and existing arithmetic +0.31 %p are each linked to their original locations and the nature of their analyses.
Requirement and applicability: Required
Application exceptions: The original +0.31 %p is reused solely as historical arithmetic; no formal model estimate, formal CI, or individual risk rate is generated.
Why this condition is needed: This is needed to avoid turning the changes in both arms, the P value, and the arithmetic difference into different analyses or clinical risk rates.
Referenced methods: C06: M03 §3.2.4, M15 §15.3.1–15.3.3; adaptations of outcomes to the specific question were developed internally / H03: M19 §19.2.2–19.2.4, M03 §3.2.3; internal application / E04: M08 §8.2.2, M15 §15.3.1; internal application. Reason for adapting this to the comparative HbA1c harm question: This is needed to avoid turning the changes in both arms, the P value, and the arithmetic difference into different analyses or clinical risk rates. No new clinical causality/grade judgment was made, and no official methodology was applied.

N20 · Have the formal between-group HbA1c change estimate, SE, and CI been verified?

Required materials and conditions: A formal between-group change-estimate table, model, paired variance, denominator, and confidence interval
Conditions for verification: The formal between-group change estimate and SE/CI appropriate to the selected comparison, time point, and analysis are verified from the original results.
Requirement and applicability: Required
Application exceptions: Do not reconstruct an interval or standardized effect using the rounded P=.048, end-of-study SEs, or 52/49.
Why this condition is needed: This is needed to avoid establishing the magnitude and precision of harm from significance or a simple mean difference alone.
Referenced methods: C07: M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; adaptations for specific designs were developed internally / E04: M08 §8.2.2, M15 §15.3.1; internal application / E05: M15 §15.3.1–15.3.3; internal application. Reason for adapting this to the comparative HbA1c harm question: This is needed to avoid establishing the magnitude and precision of harm from significance or a simple mean difference alone. No new clinical causality/grade judgment was made, and no official methodology was applied.

N21 · Have the matching prospective registration, protocol, SAP, and handling of multiplicity been verified?

Required materials and conditions: The matching ADVENT registration, original protocol, SAP, and information on analysis changes/multiplicity
Conditions for verification: Agreement or changes in endpoints, time points, models, and multiplicity between the matching prospective ADVENT plan and actual results can be verified.
Requirement and applicability: Required
Application exceptions: A null registration_id and an unobtained plan do not establish that the study was unregistered or selectively reported. Do not attach another registration or protocol to ADVENT.
Why this condition is needed: This is needed to avoid treating a reported primary (1st) endpoint as completed verification against the planned analysis.
Referenced methods: C09: M04 §4.5, §4.6.3; the limits of the current data conversion follow the user-defined scope and internal design / E06: M08 Table 8.2.a, M04 §4.6.3; internal application. Reason for adapting this to the comparative HbA1c harm question: This is needed to avoid treating a reported primary (1st) endpoint as completed verification against the planned analysis. No new clinical causality/grade judgment was made, and no official methodology was applied.

N22 · Has a validated threshold for the clinical importance of this HbA1c difference been identified?

Required materials and conditions: A validated importance threshold, paired variance, and patient-importance information for this HbA1c comparison
Conditions for verification: An important-difference threshold or a justified interpretation of the corresponding standardized effect appropriate to this population, add-on strategy, and duration is verified.
Requirement and applicability: Required; interpretation of magnitude
Application exceptions: Do not turn EX into no numerical value, no effect, or failure to meet a threshold, and do not invent an arbitrary MCID, minimum n, or duration.
Why this condition is needed: This is needed to distinguish an increase signal from the magnitude of clinically important deterioration.
Referenced methods: E05: M15 §15.3.1–15.3.3; internal application / H09: Chamgap's own interpretive boundaries. The M19 principles are referenced; no official causality tool was applied. Reason for adapting this to the comparative HbA1c harm question: This is needed to distinguish an increase signal from the magnitude of clinically important deterioration. No new clinical causality/grade judgment was made, and no official methodology was applied.

N23 · For the 1,000 mg arm in the same ADVENT trial, have the HbA1c difference and uncertainty been verified?

Required materials and conditions: The 1,000 mg arm's HbA1c results, between-group estimate/interval, and denominator in the same trial
Conditions for verification: For the 1,000 mg arm, the actual between-group HbA1c difference, denominator, and interval are verified and distinguished from the selected 1,500 mg comparison.
Requirement and applicability: Supplementary; required for interpreting dose-related/opposing findings
Application exceptions: Do not interpret nonsignificance at P=.16 as an effect of 0, equivalence, a harmless dose, or an established dose–response relationship.
Why this condition is needed: This is needed to avoid turning another dose in the same trial into independent replication or evidence of safety at all lower doses.
Referenced methods: C08: M04 §4.6.3, M15 §15.3.1–15.3.3; separation of statuses was developed internally / E07: M04 §4.6.1–4.6.2, M15 §15.3.1; internal application / E08: M03 §3.2.1–3.2.4; details of dose, persistence, and effect modification were developed internally / H07: M04 §4.6.1–4.6.2; adaptation for harm data was developed internally. Reason for adapting this to the comparative HbA1c harm question: This is needed to avoid turning another dose in the same trial into independent replication or evidence of safety at all lower doses. No new clinical causality/grade judgment was made, and no official methodology was applied.

N24 · For the 1,000 mg arm, does baseline HbA1c agree between the table and abstract?

Required materials and conditions: The corresponding value in the original Table 1 and abstract, and any correction or author explanation
Conditions for verification: For the same 1,000 mg arm, baseline HbA1c agrees between the table and abstract, or the difference is resolved by evidence of a correction.
Requirement and applicability: Supplementary; required for verifying a conflict concerning the same fact
Application exceptions: Do not treat successful documentation of a conflict as fulfillment of the data-consistency condition. Do not change values for the currently selected arms.
Why this condition is needed: This is needed to avoid arbitrarily correcting conflicting values or claiming that they have been reconciled as different endpoints.
Referenced methods: C08: M04 §4.6.3, M15 §15.3.1–15.3.3; separation of statuses was developed internally / E03: M08 Table 8.2.a, M03 §3.2.4; internal application. Reason for adapting this to the comparative HbA1c harm question: This is needed to avoid arbitrarily correcting conflicting values or claiming that they have been reconciled as different endpoints. No new clinical causality/grade judgment was made, and no official methodology was applied.

N25 · Has the original material for the no-change conference presentation cited by the study report been verified?

Required materials and conditions: The original conference abstract, presentation identity, population/intervention, results, and trial-linkage information
Conditions for verification: Material is available to directly verify the identity, population, intervention, HbA1c results, and family relationships of the original presentation.
Requirement and applicability: Supplementary; required for interpreting replication/opposing evidence
Application exceptions: Do not assign a unique trial count or participant count to a presentation whose relationship to the same trial or another family is unverified.
Why this condition is needed: This is needed to avoid elevating the study report's secondhand citation to a newly read independent presentation result.
Referenced methods: C02: M04 §4.6.1–4.6.2: distinction between studies and reports; internal application to cohort/outcome linkage / C03: M04 §4.5–4.6: data-collection/selection principles; the distinction between access and reading and the hyperlink conventions were developed internally / C08: M04 §4.6.3, M15 §15.3.1–15.3.3; separation of statuses was developed internally / H07: M04 §4.6.1–4.6.2; adaptation for harm data was developed internally. Reason for adapting this to the comparative HbA1c harm question: This is needed to avoid elevating the study report's secondhand citation to a newly read independent presentation result. No new clinical causality/grade judgment was made, and no official methodology was applied.

N26 · Have the actual formulation, comparison, timing, and between-group HbA1c results of ADMIT been verified?

Required materials and conditions: ADMIT treatment/run-in, factorial co-interventions, diabetic-subgroup results tables, denominators, tests/intervals, and corrections
Conditions for verification: The IR formulation, different dose/run-in/population, time point of interest, between-group results, and uncertainty in ADMIT are verified.
Requirement and applicability: Supplementary; required for interpreting indirect/opposing comparisons
Application exceptions: Retain the ADMIT abstract/table P-value discrepancy as originally recorded; do not newly fill in figures absent from the current retained version.
Why this condition is needed: This is needed to avoid turning within-arm maintenance in IR ADMIT into a null between-group effect for NIASPAN ER or replication of the exact comparison.
Referenced methods: C05: M03 §3.2.2–3.2.3; reverse-direction labeling and test adaptations were developed internally / C06: M03 §3.2.4, M15 §15.3.1–15.3.3; adaptations of outcomes to the specific question were developed internally / C08: M04 §4.6.3, M15 §15.3.1–15.3.3; separation of statuses was developed internally / E04: M08 §8.2.2, M15 §15.3.1; internal application / E07: M04 §4.6.1–4.6.2, M15 §15.3.1; internal application / H03: M19 §19.2.2–19.2.4, M03 §3.2.3; internal application. Reason for adapting this to the comparative HbA1c harm question: This is needed to avoid turning within-arm maintenance in IR ADMIT into a null between-group effect for NIASPAN ER or replication of the exact comparison. No new clinical causality/grade judgment was made, and no official methodology was applied.

N27 · Have the actual release formulation, measurements, and period-specific contrasts in the Garg crossover trial been verified?

Required materials and conditions: The product release formulation, assay method, crossover sequence/periods, paired results, and denominators in the original Garg full text
Conditions for verification: The crossover trial's release formulation, measurement method, paired period comparison, and denominator/interval are verified.
Requirement and applicability: Supplementary; required for interpreting indirect evidence
Application exceptions: Do not calculate the 13-participant crossover trial as an independent-arm design or treat glycosylated hemoglobin as a verified equivalent HbA1c assay.
Why this condition is needed: This is needed to avoid automatically equating the nicotinic acid name and glycosylated hemoglobin results with the selected ER HbA1c change.
Referenced methods: C05: M03 §3.2.2–3.2.3; reverse-direction labeling and test adaptations were developed internally / C06: M03 §3.2.4, M15 §15.3.1–15.3.3; adaptations of outcomes to the specific question were developed internally / C07: M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; adaptations for specific designs were developed internally / E04: M08 §8.2.2, M15 §15.3.1; internal application / E07: M04 §4.6.1–4.6.2, M15 §15.3.1; internal application / H03: M19 §19.2.2–19.2.4, M03 §3.2.3; internal application. Reason for adapting this to the comparative HbA1c harm question: This is needed to avoid automatically equating the nicotinic acid name and glycosylated hemoglobin results with the selected ER HbA1c change. No new clinical causality/grade judgment was made, and no official methodology was applied.

N28 · Have the ingredient, product, and comparison in the report of improvement with low-dose niacin and sitagliptin been verified?

Required materials and conditions: Ingredient/product specifications, sitagliptin/chromium arm composition, comparator, and HbA1c results tables for the Karim trial
Conditions for verification: The actual molecule, product, dose, co-treatment arms, comparator, and comparative scope of the HbA1c results are verified.
Requirement and applicability: Supplementary; required for determining the applicability of opposing evidence
Application exceptions: Do not fill in NIASPAN for the unverified nicotinic acid/amide identity and product of the 14 mg/day niacin.
Why this condition is needed: This is needed to retain results in the opposite direction while preventing findings with a different dose and co-treatment from being repurposed for the selected prescription ER comparison.
Referenced methods: C05: M03 §3.2.2–3.2.3; reverse-direction labeling and test adaptations were developed internally / C06: M03 §3.2.4, M15 §15.3.1–15.3.3; adaptations of outcomes to the specific question were developed internally / C08: M04 §4.6.3, M15 §15.3.1–15.3.3; separation of statuses was developed internally / E02: M03 §3.2.3, M08 §8.2.2–8.2.3; internal application / E07: M04 §4.6.1–4.6.2, M15 §15.3.1; internal application / H03: M19 §19.2.2–19.2.4, M03 §3.2.3; internal application. Reason for adapting this to the comparative HbA1c harm question: This is needed to retain results in the opposite direction while preventing findings with a different dose and co-treatment from being repurposed for the selected prescription ER comparison. No new clinical causality/grade judgment was made, and no official methodology was applied.

N29 · Has evidence of independent replication of the exact NIASPAN comparison been verified?

Required materials and conditions: Links between unique trials and reports, and independent results tables, for the exact comparison
Conditions for verification: Results from an independent family matching the product, dose, population, policy, time point, and HbA1c comparison are directly verified.
Requirement and applicability: Supplementary; required for interpreting replication/generalizability
Application exceptions: Preserve the original R1 and the single direct family. Do not newly judge the number of studies worldwide, the total number of unique participants, or the absence of replication.
Why this condition is needed: This is needed to avoid counting reports of the same dose arms, regulatory secondhand citations, reviews, or registrations as independent replication trials.
Referenced methods: C02: M04 §4.6.1–4.6.2: distinction between studies and reports; internal application to cohort/outcome linkage / E07: M04 §4.6.1–4.6.2, M15 §15.3.1; internal application / H07: M04 §4.6.1–4.6.2; adaptation for harm data was developed internally. Reason for adapting this to the comparative HbA1c harm question: This is needed to avoid counting reports of the same dose arms, regulatory secondhand citations, reviews, or registrations as independent replication trials. No new clinical causality/grade judgment was made, and no official methodology was applied.

N30 · Have funding, manufacturer-affiliated authors, and disclosed conflicts of interest in the direct trial been verified?

Required materials and conditions: Original funding information, author affiliations, product supply, speaking/stock/employment relationships, and COI disclosures
Conditions for verification: Funding, author affiliations, and disclosed relationships such as speaking/stock interests in the core trial are linked to their original locations.
Requirement and applicability: Supplementary; required for interpreting independence
Application exceptions: The presence of Kos support is not used to declare the figures invalid, nor as proof of independent funding or independent replication.
Why this condition is needed: This is needed to avoid penalizing manufacturer support/author relationships again as trial-method bias, or automatically deleting the data.
Referenced methods: C10: Chamgap's own criteria for independence and attribution. The official methodological sections used in this pilot do not warrant all of these detailed items. Reason for adapting this to the comparative HbA1c harm question: This is needed to avoid penalizing manufacturer support/author relationships again as trial-method bias, or automatically deleting the data. No new clinical causality/grade judgment was made, and no official methodology was applied.

N31 · Can the products and versions in the official ER documents, and their differences from the historical trial, be verified?

Required materials and conditions: Products, versions, dates, description/warning sections in the DailyMed/FDA documents, and information linking them to the trial product
Conditions for verification: The products, versions, and review scope of the official generic document available at the reference date and the historical NIASPAN document are distinguished.
Requirement and applicability: Supplementary; required for interpreting official safety information
Application exceptions: The current official webpages/PDFs are not newly read, and their currency or jurisdiction-specific approvals are not rechecked.
Why this condition is needed: Needed to avoid automatically treating the 2026 generic label and the 2020 NIASPAN file as manufacturing details for the original trial, the latest documents, or estimates of the trial effect.
Referenced methods: C05: M03 §3.2.2–3.2.3; reverse-direction labeling and test adaptations are internally designed / C09: M04 §4.5, §4.6.3; the limits of the current data conversion follow the user-defined scope and internal design / H08: M19 §19.1.2–19.2.4; internal application / E10: M19 §19.1.2–19.2.4; internal application. Reason for adaptation to the comparative HbA1c harm question: needed to avoid automatically treating the 2026 generic label and the 2020 NIASPAN file as manufacturing details for the original trial, the latest documents, or estimates of the trial effect. No new clinical causality/grade judgment or application of an official method was performed.

N32 · Can the collection of other harms, discontinuations, and exposure denominators in the same trial be verified?

Required materials and conditions: Trial AE definitions, collection procedures, group-specific exposure/events/discontinuations, duration data, and original locations of official warnings
Conditions for verification: Definitions, collection, group-specific person/event counts, durations, and discontinuations for other AEs in the same population under the same exposure are verified.
Requirement and applicability: Supplementary; required for interpreting overall safety
Application exceptions: H04 is adapted only to data requirements for the frequency of separate events, such as liver/muscle events; it is not imposed as a mandatory incidence requirement for the continuous mean change in HbA1c.
Why this condition is needed: Needed to avoid turning the failure to detect major liver or muscle events in a short trial, together with official warnings, into an event rate of 0 or overall safety.
Referenced methods: H01: M19 §19.1.2–19.2.4; detailed distinctions are internally designed / H04: M19 §19.1.2–19.2.4; internal application / H06: M19 §19.1.2–19.2.4, M04 §4.6.3; internal application / E10: M19 §19.1.2–19.2.4; internal application. Reason for adaptation to the comparative HbA1c harm question: needed to avoid turning the failure to detect major liver or muscle events in a short trial, together with official warnings, into an event rate of 0 or overall safety. No new clinical causality/grade judgment or application of an official method was performed.

N33 · Can data on persistent HbA1c effects, long-term complications, and rare harms be verified?

Required materials and conditions: Exposure/follow-up data on HbA1c after discontinuation, long-term complications, rare events, and vulnerable groups
Conditions for verification: Appropriate follow-up data are available to verify persistent/long-term and rare harms for the selected population and product.
Requirement and applicability: Supplementary; required for an extension to long-term/overall safety
Application exceptions: Not every long-term study is unconditionally required to answer the narrow 16-week HbA1c claim, but gaps in extended claims remain explicit.
Why this condition is needed: Needed to avoid establishing persistent effects, rare events, or risks in excluded vulnerable groups from short-term mean changes.
Referenced methods: H08: M19 §19.1.2–19.2.4; internal application / E08: M03 §3.2.1–3.2.4; details of dose, persistence, and effect modification are internally designed. Reason for adaptation to the comparative HbA1c harm question: needed to avoid establishing persistent effects, rare events, or risks in excluded vulnerable groups from short-term mean changes. No new clinical causality/grade judgment or application of an official method was performed.

N34 · Can the body text, results, and correspondence to ADVENT of the registry leads be verified?

Required materials and conditions: Official body text/history, results, and verified linkage data for DRKS00030865, NCT00108485, and NCT06378125
Conditions for verification: The official body text, results, registry links, and correspondence to the selected ADVENT comparison are directly verified.
Requirement and applicability: Supplementary; required for interpreting registrations/unpublished results
Application exceptions: Do not assert that NCT06378125 and DRKS00030865 are the same registration without a verified cross-link. Do not display historical access failures as current failures.
Why this condition is needed: Needed to avoid elevating registry completion/termination status, mirrors, or a JS shell to verified HbA1c results or replication of ADVENT.
Referenced methods: C02: the distinction between studies and reports in M04 §4.6.1–4.6.2; internal application to cohort/outcome linkage / C03: the data-collection/selection principles in M04 §4.5–4.6; the distinction between access and reading, and the hyperlink conventions, are internally designed / C09: M04 §4.5, §4.6.3; the limits of the current data conversion follow the user-defined scope and internal design / E06: M08 Table 8.2.a, M04 §4.6.3; internal application / H07: M04 §4.6.1–4.6.2; adaptation for harm data is internally designed. Reason for adaptation to the comparative HbA1c harm question: needed to avoid elevating registry completion/termination status, mirrors, or a JS shell to verified HbA1c results or replication of ADVENT. No new clinical causality/grade judgment or application of an official method was performed.

N35 · Can the actual body text, scope, and family relationships of the review, protocol, and expression-of-concern notice be verified?

Required materials and conditions: The review's included trials/results tables, protocol body text, content/scope of the expression-of-concern notice, and document links
Conditions for verification: The actual content of the S11 included trials, S12 plans, and S13 notice, and their relationships to the corresponding documents/trials, are verified.
Requirement and applicability: Supplementary; required for interpreting indirect evidence/editorial history
Application exceptions: Keep the spelling in the actual returned S13 link byte-for-byte. Do not add scope or ADVENT relevance without having read the original text of the expression-of-concern notice.
Why this condition is needed: Needed to avoid repurposing the existence of a review, an indexed protocol, or an expression-of-concern lead as confirmation of results or evidence of an ADVENT defect.
Referenced methods: C02: the distinction between studies and reports in M04 §4.6.1–4.6.2; internal application to cohort/outcome linkage / C03: the data-collection/selection principles in M04 §4.5–4.6; the distinction between access and reading, and the hyperlink conventions, are internally designed / C08: M04 §4.6.3, M15 §15.3.1–15.3.3; separation of statuses is internally designed / C09: M04 §4.5, §4.6.3; the limits of the current data conversion follow the user-defined scope and internal design / E06: M08 Table 8.2.a, M04 §4.6.3; internal application / H07: M04 §4.6.1–4.6.2; adaptation for harm data is internally designed. Reason for adaptation to the comparative HbA1c harm question: needed to avoid repurposing the existence of a review, an indexed protocol, or an expression-of-concern lead as confirmation of results or evidence of an ADVENT defect. No new clinical causality/grade judgment or application of an official method was performed.

N36 · Does this HbA1c comparison also answer questions about incident diabetes or cardiovascular/complication events?

Required materials and conditions: Definitions, denominators, follow-up, and between-group results for incident diabetes and cardiovascular/complication events in the selected comparison
Conditions for verification: Direct results are available to address the separate clinical-event question in the same population with the same product and comparison.
Requirement and applicability: Supplementary; required for an extension to clinical events
Application exceptions: Because the original question concerns HbA1c change itself, event trials are not imposed as an invariably mandatory condition for verifying that result.
Why this condition is needed: Needed to avoid treating a mean difference in a surrogate as an increase in event incidence or long-term complications.
Referenced methods: C06: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are internally designed / E09: M03 §3.2.4; internally defined extension boundaries / H08: M19 §19.1.2–19.2.4; internal application / H09: Chamgap's own interpretive boundaries. The M19 principles are referenced; no official causality tool was applied. Reason for adaptation to the comparative HbA1c harm question: needed to avoid treating a mean difference in a surrogate as an increase in event incidence or long-term complications. No new clinical causality/grade judgment or application of an official method was performed.

N37 · Are current summary reading, each material's historical access/access date, and current external nonreading distinguished?

Required materials and conditions: Actual access, acquisition, and reading events for each material, original locations and dates, and hashes of the retained inputs
Conditions for verification: Local retained-summary reading, historical access/access dates for the 13 bibliographic records (citation), the original review date, and current unattempted/unread external access are recorded separately.
Requirement and applicability: Required
Application exceptions: Do not describe current unattempted external access as access failure; use a historical access date only for a bibliographic record (citation) that actually has an access_date. Do not mark older separate files as having been read merely because they are referenced.
Why this condition is needed: Needed to avoid treating historical full-text/abstract/access-failure records (full_text/abstract/access_failure) and original access dates as actions performed in this review.
Referenced methods: C03: the data-collection/selection principles in M04 §4.5–4.6; the distinction between access and reading, and the hyperlink conventions, are internally designed / C09: M04 §4.5, §4.6.3; the limits of the current data conversion follow the user-defined scope and internal design. Reason for adaptation to the comparative HbA1c harm question: needed to avoid treating historical full-text/abstract/access-failure records (full_text/abstract/access_failure) and original access dates as actions performed in this review. No new clinical causality/grade judgment or application of an official method was performed.

N38 · Are the original C46, 7 axes, document quality, and new condition statuses distinguished in what they describe?

Required materials and conditions: Original records of the assessment, axes, score meaning, document quality, and version
Conditions for verification: The clinical-harm claim/increase designation (clinical_harm_claim/increase), C46 and B/S/R1/I0/EX/B2/CX, and the meaning of document self-review grade A are each linked to their original locations.
Requirement and applicability: Required
Application exceptions: Preserve the original missing values, false values, axes, and score unchanged; do not change them to F or efficacy not_applicable merely because this is a harm claim.
Why this condition is needed: Needed to avoid reusing the original clinical-harm grade as a safety grade, risk rate, document-quality grade, or criterion-fulfillment rate.
Referenced methods: C01: the question-clarification principles in M03 §3.1, §3.2.1–3.2.4; detailed separation rules are internally designed / C09: M04 §4.5, §4.6.3; the limits of the current data conversion follow the user-defined scope and internal design / H09: Chamgap's own interpretive boundaries. The M19 principles are referenced; no official causality tool was applied. Reason for adaptation to the comparative HbA1c harm question: needed to avoid reusing the original clinical-harm grade as a safety grade, risk rate, document-quality grade, or criterion-fulfillment rate. No new clinical causality/grade judgment or application of an official method was performed.

N39 · Are the current verification scope, evidence reference date, original server metadata, and update events stated?

Required materials and conditions: Evidence/review dates, actual retained search/selection records, versions, and update/correction events
Conditions for verification: The original reference date of 2026-09-15, the scope of review of current retained inputs, actual review dates, unverified information, update events, and nondeployment are distinguished.
Requirement and applicability: Required
Application exceptions: Distinguish the historical dates in evidence_cutoff/verified_date from the current review date, and do not interpret the original first-publication date or the missing deployment timestamp (deployed_at, null) as a new deployment event.
Why this condition is needed: Needed to avoid overstating conversion of retained materials as a current comprehensive search, completed public release, or absence of studies worldwide.
Referenced methods: C09: M04 §4.5, §4.6.3; the limits of the current data conversion follow the user-defined scope and internal design / E06: M08 Table 8.2.a, M04 §4.6.3; internal application. Reason for adaptation to the comparative HbA1c harm question: needed to avoid overstating conversion of retained materials as a current comprehensive search, completed public release, or absence of studies worldwide. No new clinical causality/grade judgment or application of an official method was performed.

Referenced methods and the sections actually reviewed

M03 · Cochrane Handbook 6.5 (2024), chapter updated 2023-08

Official methodology · §3.1, §3.2.1–3.2.3, MECIR C5/C7/C13

Referenced principle: Clearly record the question, eligibility criteria, and reasons for changes, and distinguish variations in the intervention.
Extent of review: Reused the original HTML bytes/SHA copies and historical principles from 1585's 5 retained methods. This was not new full-text methods reading or official assessment/certification.

M04 · Cochrane Handbook 6.5.1 (2025), chapter updated 2025-03

Official methodology · §4.5, §4.6.1–4.6.3, MECIR C42

Referenced principle: Distinguish studies from reports and link them; do not omit a study solely because results were not reported.
Extent of review: Reused the original HTML bytes/SHA copies and historical principles from 1585's 5 retained methods. This was not new full-text methods reading or official assessment/certification.

M08 · Cochrane Handbook 6.5 (2024), chapter updated 2019-10

Official methodology · §8.1–8.2.3, Table 8.2.a

Referenced principle: Fix the outcome and effect of interest when reviewing randomization, departures, missing data, measurement, and selective reporting.
Extent of review: Reused the original HTML bytes/SHA copies and historical principles from 1585's 5 retained methods. This was not new full-text methods reading or official assessment/certification.

M15 · Cochrane Handbook 6.5 (2024), chapter updated 2023-08

Official methodology · §15.2.4, §15.3.1–15.3.3

Referenced principle: Distinguish effect estimates, intervals, importance, and application. Sample size alone does not determine precision.
Extent of review: Reused the original HTML bytes/SHA copies and historical principles from 1585's 5 retained methods. This was not new full-text methods reading or official assessment/certification.

M19 · Cochrane Handbook 6.5 (2024), chapter updated 2019-10

Official methodology · §19.1.2, §19.2.1–19.2.4

Referenced principle: Questions about harms may require designs, populations, and follow-up different from those for efficacy. Case reports do not establish incidence.
Extent of review: Reused the original HTML bytes/SHA copies and historical principles from 1585's 5 retained methods. This was not new full-text methods reading or official assessment/certification.

What the statuses mean

Met: The specific narrow identity, definition, attribution of verified numbers, policy, or boundary of the actual record is verified. This does not certify clinical harm, a formal interval, or overall safety.
Partly verified: Some actual information is verified in the original material, but the product, denominator, analysis, or full estimate for the question remains incomplete.
Unverified: Cannot be established within the current retained scope. This does not mean an effect of 0, absence of studies worldwide, or current access failure.
Conflicting information: Original reports of the same fact do not agree. Successful recording of the conflict is distinguished from verification that the clinical data are consistent.
Not reported: Limited to nonreporting within the explicitly stated material accessed at the time. This is not a claim of absence throughout a full text left unread in this review.
Not applicable: Used when there is a specific reason why the applicability conditions of the current question are not met. Not a substitute for unverified or unread status.
Inaccessible: Historical failures are distinguished from actual current access failures. This status is not assigned to unattempted external access in this review.
Review incomplete: Limited to the current nonperformance of comparisons against external original material; distinguished from the local retained-summary review that was actually completed.

Change history

2026-11-01 · Public page/material version 1.0

The public view and materials were prepared from the existing 39 items. No new clinical search, change in verification status, or scoring was performed.

The stored-material review date (2026-10-05) and original evidence cut-off (2026-09-15) were retained unchanged.

Researcher downloads

These materials provide the same evidence, scope and verification status as this page.

View all item details

N01 · Which population, intervention, comparator, time period and endpoint define the comparative harm claim?

Current findings: The selected original claim concerns adults with stable type 2 diabetes and dyslipidemia and an increase in HbA1c. It is a quantitative harm question comparing the oral NIASPAN ER add-on strategy with matching placebo over a total of 16 weeks.
Verification status: Met
Materials actually read: Summary reading: the material at the exact identified location in the retained source summary was read. The linked external material was not read in this review.
Why unverified: The actual claim identity and comparison scope are verified. This status does not establish the clinical importance of the increase or harm from all niacin interventions.
Reason for missing information: There is no gap in the boundaries of the current separate question; detailed analyses and long-term extensions are considered under separate criteria.
Required materials and conditions: Material linking the identity of the current claim with the actual population, intervention, comparator, endpoint and time point
Materials to obtain first: Material linking the identity of the current claim with the actual population, intervention, comparator, endpoint and time point
Further research: Compare the current manuscript with the trial's actual comparison, and record the reason and the scope before and after any boundary change.
Remaining uncertainty: There is no gap in the boundaries of the current separate question; detailed analyses and long-term extensions are considered under separate criteria. No new clinical effect, risk rate, individual response or grade is calculated or judged.
Conditions for verification: The actual original material specifies the boundaries: stable type 2 diabetes and dyslipidemia, adjustable usual care, NIASPAN ER added versus matching placebo, and change over a total of 16 weeks in HbA1c.
Why this condition is needed: Needed to distinguish the quantitative harm claim of an HbA1c increase from glycemic-improvement efficacy and a general safety indicator.
Application exceptions: Do not change the clinical-harm/increase classification (clinical_harm_claim/increase) to reduced efficacy or a safety-only flag (safety_only), or include other niacin interventions or other clinical endpoints.
Referenced methods: C01: Question-clarification principles in M03 §3.1, §3.2.1–3.2.4; detailed separation rules are internally designed / C04: M03 §3.2.1; detailed population criteria are internally designed / C05: M03 §3.2.2–3.2.3; reverse-direction labeling and test adaptations are internally designed / C06: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are internally designed / H09: Chamgap's own interpretive boundaries. The M19 principles are referenced; no official causality tool was applied. Reason for adapting this to comparative HbA1c harm: needed to distinguish the quantitative harm claim of an HbA1c increase from glycemic-improvement efficacy and a general safety indicator. No new clinical causality/grade judgment or official methodological procedure was performed.

Related sources S01

N02 · Are the actual ingredient, product, release formulation and route verified?

Current findings: The intervention is NIASPAN (Kos), single-ingredient nicotinic acid in ER oral tablets. Nicotinamide, NR, NMN, no-flush preparations, nicotine and IR/SR substitutes are not treated as the same intervention. Equivalence of a separate salt was not verified.
Verification status: Met
Materials actually read: Summary reading: the material at the exact identified location in the retained source summary was read. The linked external material was not read in this review.
Why unverified: The selected ingredient, product, release formulation, route and exclusions are verified. This does not mean that the manufacturing process, batch or excipients have also been verified.
Reason for missing information: The separate salt, manufacturing batch and exact excipients remain unverified, separately from this product-identity verification.
Required materials and conditions: The core trial's product name, ingredient, release formulation and route, and the corresponding locations in the official product description
Materials to obtain first: The core trial's product name, ingredient, release formulation and route, and the corresponding locations in the official product description
Further research: Compare the trial product's ingredient and release formulation with the original description, and consider other molecules/formulations only through their own direct evidence.
Remaining uncertainty: The separate salt, manufacturing batch and exact excipients remain unverified, separately from this product-identity verification. No new clinical effect, risk rate, individual response or grade is calculated or judged.
Conditions for verification: The original material distinguishes the single active ingredient nicotinic acid, NIASPAN (Kos), ER oral tablets, and the excluded molecules/formulations.
Why this condition is needed: Needed to avoid transferring results for NIASPAN extended-release nicotinic acid to nicotinamide or IR/SR formulations.
Application exceptions: Do not resolve an unverified separate salt designation by assuming equivalence to another salt. Distinguish the null value/not_applicable status for plant-part information (botanical_part) from the unverified manufacturing origin.
Referenced methods: C05: M03 §3.2.2–3.2.3; reverse-direction labeling and test adaptations are internally designed / H03: M19 §19.2.2–19.2.4, M03 §3.2.3; internal application. Reason for adapting this to comparative HbA1c harm: needed to avoid transferring results for NIASPAN extended-release nicotinic acid to nicotinamide or IR/SR formulations. No new clinical causality/grade judgment or official methodological procedure was performed.

Related sources S01 S06

N03 · Is the actual information on manufacturing origin, batch and excipients verified?

Current findings: The raw material's manufacturing origin, such as synthesis or fermentation, the batch and the exact excipients are unverified. Plant-part information has a null value/not_applicable status, whereas manufacturing origin has a null value/unverified status; these are different.
Verification status: Unverified
Materials actually read: Summary reading: the material at the exact identified location in the retained source summary was read. The linked external material was not read in this review.
Why unverified: The retained material does not provide evidence that establishes the product's detailed manufacturing information. Do not erase this gap by using the Not applicable designation for this chemical ingredient's plant-part information.
Reason for missing information: Specifications for the actual manufacturing origin, trial batch and excipients are needed.
Required materials and conditions: Specifications for the trial product's manufacturing process, raw-material origin, batch and excipients
Materials to obtain first: Specifications for the trial product's manufacturing process, raw-material origin, batch and excipients
Further research: If permitted product material is obtained, compare it with the trial batch and do not inherit information from another product.
Remaining uncertainty: Specifications for the actual manufacturing origin, trial batch and excipients are needed. No new clinical effect, risk rate, individual response or grade is calculated or judged.
Conditions for verification: Direct material is available to verify the selected product's manufacturing origin, batch and excipients.
Why this condition is needed: Knowing a product name and knowing its actual manufacturing origin, batch and excipients are different levels of information.
Application exceptions: Although plant-part information is not applicable to this chemical ingredient, do not change the unverified/null manufacturing origin to Not applicable.
Referenced methods: C05: M03 §3.2.2–3.2.3; reverse-direction labeling and test adaptations are internally designed. Reason for adapting this to comparative HbA1c harm: knowing a product name and knowing its actual manufacturing origin, batch and excipients are different levels of information. No new clinical causality/grade judgment or official methodological procedure was performed.

Related sources S01 S06

N04 · Are the trial's diagnosis, stability, age and inclusion/exclusion criteria verified?

Current findings: Participants were men and women aged 21 or older with stable type 2 diabetes and dyslipidemia. Two measurements showed HbA1c ≤ 9% and fasting glucose ≤ 200 mg/dL. Exclusions recorded included relevant liver disease, a history of gout or peptic ulcer, and thiazolidinedione use.
Verification status: Met
Materials actually read: Summary reading: the material at the exact identified location in the retained source summary was read. The linked external material was not read in this review.
Why unverified: This verifies the population and entry criteria specified in the original material. It does not verify the magnitude of harm in all people with diabetes or in excluded vulnerable groups.
Reason for missing information: Detailed subgroups, representativeness and deficiency status fall within a separate evidence scope.
Required materials and conditions: Inclusion/exclusion criteria, diagnosis, baseline-characteristics table and material verifying stability
Materials to obtain first: Inclusion/exclusion criteria, diagnosis, baseline-characteristics table and material verifying stability
Further research: Compare the actual recruited population's diagnoses and entry criteria with the claim's target population, and keep direct results in other populations separate.
Remaining uncertainty: Detailed subgroups, representativeness and deficiency status fall within a separate evidence scope. No new clinical effect, risk rate, individual response or grade is calculated or judged.
Conditions for verification: The original material specifies age 21 or older, stable type 2 diabetes and dyslipidemia, diagnoses, entry criteria, sex and major exclusions.
Why this condition is needed: Needed to avoid applying the selected trial's results unchanged to people with diabetes generally or to healthy people.
Application exceptions: Keep participants' baseline niacin-deficiency status separately unverified, and do not invent detailed subgroup effects.
Referenced methods: C04: M03 §3.2.1; detailed population criteria are internally designed / H05: Design considerations in M19 §19.2.2–19.2.4; detailed recording of confounding is internally designed. Reason for adapting this to comparative HbA1c harm: needed to avoid applying the selected trial's results unchanged to people with diabetes generally or to healthy people. No new clinical causality/grade judgment or official methodological procedure was performed.

Related sources S01

N05 · Are baseline niacin status, deficiency classification and total dietary intake verified?

Current findings: Baseline niacin concentrations, deficiency classification and total dietary niacin could not be verified in the text accessed at the time. This trial is not defined as a deficiency-treatment trial.
Verification status: Not reported
Materials actually read: Summary reading: the material at the exact identified location in the retained source summary was read. The linked external material was not read in this review.
Why unverified: The original record of unknowns specifies the scope as not_reported_in_accessed_text. The external full text was not read in this review, so this is not extended to nonreporting throughout the current full text.
Reason for missing information: Baseline niacin/dietary information beyond what was verified at the time, and its exact original locations, are unavailable.
Required materials and conditions: Baseline niacin measurements, deficiency-classification criteria and data on total dietary niacin
Materials to obtain first: Baseline niacin measurements, deficiency-classification criteria and data on total dietary niacin
Further research: Review direct material while distinguishing baseline status from drug and dietary exposure, and treat results of deficiency treatment as a separate question.
Remaining uncertainty: Baseline niacin/dietary information beyond what was verified at the time, and its exact original locations, are unavailable. No new clinical effect, risk rate, individual response or grade is calculated or judged.
Conditions for verification: Participant-specific data are available on baseline niacin measurement, deficiency classification and total dietary intake.
Why this condition is needed: Needed to avoid treating deficiency correction and prescription-drug addition in nondeficient participants as the same question.
Application exceptions: Do not extend information not identified in the text accessed at the time into a claim that it was unreported throughout the entire paper, or into evidence that deficiency was absent.
Referenced methods: C04: M03 §3.2.1; detailed population criteria are internally designed / H05: Design considerations in M19 §19.2.2–19.2.4; detailed recording of confounding is internally designed. Reason for adapting this to comparative HbA1c harm: needed to avoid treating deficiency correction and prescription-drug addition in nondeficient participants as the same question. No new clinical causality/grade judgment or official methodological procedure was performed.

Related sources S01

N06 · Are the actual planned titration, target dose and dosing frequency verified?

Current findings: The schedule was 1 dose per 1 day at bedtime, titrated through week 1 at 375 mg/day, week 2 at 500 mg/day, week 3 at 750 mg/day and week 4 at 1,000 mg/day, followed by a target for weeks 5–16 of 1,500 mg/day. The target tablet count was recorded as two 750 mg tablets.
Verification status: Met
Materials actually read: Summary reading: the material at the exact identified location in the retained source summary was read. The linked external material was not read in this review.
Why unverified: The nominal plan in the original treatment schedule is verified. This does not verify that every participant actually maintained this dose.
Reason for missing information: Individual adherence, target doses reached and change histories remain separately unverified.
Required materials and conditions: Trial treatment schedule, target dose, tablet count and data on actual adherence/dose reached
Materials to obtain first: Trial treatment schedule, target dose, tablet count and data on actual adherence/dose reached
Further research: Compare planned administration with actual treatment histories, distinguishing nominal dose, dose reached and cumulative exposure.
Remaining uncertainty: Individual adherence, target doses reached and change histories remain separately unverified. No new clinical effect, risk rate, individual response or grade is calculated or judged.
Conditions for verification: Bedtime administration at 1 dose per 1 day, weekly titration, target dose and tablet count are linked to the actual plan.
Why this condition is needed: Needed to avoid displaying the target dose as a fixed dose actually taken throughout the entire period.
Application exceptions: The study schedule is not a personal dosing instruction, and actual adherence/doses reached are distinguished from the planned titration schedule.
Referenced methods: C05: M03 §3.2.2–3.2.3; reverse-direction labeling and test adaptations are internally designed / H02: Design-specific harm questions in M19 §19.2; details of temporal relationships are internally designed. Reason for adapting this to comparative HbA1c harm: needed to avoid displaying the target dose as a fixed dose actually taken throughout the entire period. No new clinical causality/grade judgment or official methodological procedure was performed.

Related sources S01

N07 · Are the titration period, target-dose period and total follow-up period separately identified and verified?

Current findings: The planned total treatment of 16 weeks includes 4 weeks of titration, and the target-dose period is 12 weeks. Long-term follow-up for the selected HbA1c question has no recorded value (null).
Verification status: Met
Materials actually read: Summary reading: the material at the exact identified location in the retained source summary was read. The linked external material was not read in this review.
Why unverified: The actual planned timeline is specified. The 16-week results do not verify persistence, rare harms or long-term complications.
Reason for missing information: Persistence of effects after discontinuation and follow-up for long-term harms remain separately unverified.
Required materials and conditions: Schedules for treatment, titration, target-dose maintenance and end of follow-up, together with long-term follow-up material
Materials to obtain first: Schedules for treatment, titration, target-dose maintenance and end of follow-up, together with long-term follow-up material
Further research: Link the timeline to actual exposure and measurement schedules, and examine persistence after discontinuation or long-term outcomes through separate follow-up.
Remaining uncertainty: Persistence of effects after discontinuation and follow-up for long-term harms remain separately unverified. No new clinical effect, risk rate, individual response or grade is calculated or judged.
Conditions for verification: The planned total of 16 weeks, 4 weeks of titration and target dose in weeks 5–16 are distinguished from the absence of long-term follow-up.
Why this condition is needed: Needed to avoid turning the total of 16 weeks into fixed exposure to the target of 1,500 mg/day for 16 weeks, or into long-term follow-up.
Application exceptions: Do not use the planned 12-week target-dose period as a new clinical minimum duration or long-term safety criterion.
Referenced methods: C06: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are internally designed / H02: Design-specific harm questions in M19 §19.2; details of temporal relationships are internally designed / H08: M19 §19.1.2–19.2.4; internal application. Reason for adapting this to comparative HbA1c harm: needed to avoid turning the total of 16 weeks into fixed exposure to the target of 1,500 mg/day for 16 weeks, or into long-term follow-up. No new clinical causality/grade judgment or official methodological procedure was performed.

Related sources S01

N08 · Is the actual composition of the matching placebo verified?

Current findings: There is a record of a randomized, double-blind comparison using matching placebo. Its exact composition beyond the description of matching placebo is unverified.
Verification status: Partly verified
Materials actually read: Summary reading: the material at the exact identified location in the retained source summary was read. The linked external material was not read in this review.
Why unverified: The comparison type is verified, but details of the actual composition, appearance and establishment of blinding were not verified.
Reason for missing information: The placebo's exact composition and appearance, and blinding-assessment material, are unavailable.
Required materials and conditions: Material on placebo manufacture, composition, appearance, corresponding tablets and blinding assessment
Materials to obtain first: Material on placebo manufacture, composition, appearance, corresponding tablets and blinding assessment
Further research: Compare the placebo description with the trial product, distinguishing the unverified details of composition and blinding.
Remaining uncertainty: The placebo's exact composition and appearance, and blinding-assessment material, are unavailable. No new clinical effect, risk rate, individual response or grade is calculated or judged.
Conditions for verification: The matching placebo and a direct description of its composition, appearance and whether it contained active ingredients are verified.
Why this condition is needed: Needed to avoid turning the term matching placebo into verification of its exact ingredients or complete blinding.
Application exceptions: Do not use unverified placebo details as evidence that there was no placebo or as confirmation that blinding failed.
Referenced methods: C05: M03 §3.2.2–3.2.3; reverse-direction labeling and test adaptations are internally designed / H03: M19 §19.2.2–19.2.4, M03 §3.2.3; internal application / E02: M03 §3.2.3, M08 §8.2.2–8.2.3; internal application. Reason for adapting this to comparative HbA1c harm: needed to avoid turning the term matching placebo into verification of its exact ingredients or complete blinding. No new clinical causality/grade judgment or official methodological procedure was performed.

Related sources S01

N09 · Are the common policies on diabetes-treatment adjustment, statins and aspirin verified?

Current findings: Under the common diet and diabetes-care policy, diabetes medications could be increased or added. Only existing statin users continued statins; they were not common treatment given to everyone. Other lipid-lowering medications underwent washout, and aspirin to prevent flushing was permitted but was not mandatory common treatment.
Verification status: Met
Materials actually read: Summary reading: the material at the exact identified location in the retained source summary was read. The linked external material was not read in this review.
Why unverified: The care policy in the original comparison is specified. This does not mean that actual concomitant medications, doses or times of addition were the same for every participant.
Reason for missing information: Details of the treatment changes actually made in each arm are considered under the next criterion.
Required materials and conditions: Trial rules for common care, diabetes-medication adjustment, statins and permitted aspirin use
Materials to obtain first: Trial rules for common care, diabetes-medication adjustment, statins and permitted aspirin use
Further research: Distinguish the common care policy from actual medication changes, include that policy in the effect of interest, and examine how departures by arm were handled.
Remaining uncertainty: Details of the treatment changes actually made in each arm are considered under the next criterion. No new clinical effect, risk rate, individual response or grade is calculated or judged.
Conditions for verification: Permission to change usual diabetes care, continuation of existing statins, the absence of a statin requirement for everyone, and the policy permitting but not requiring aspirin are verified.
Why this condition is needed: Needed to distinguish a common policy from a claim that everyone actually received identical concomitant medication.
Application exceptions: Do not automatically judge diabetes-medication adjustment as contamination or design failure; preserve it as the care policy in the comparison of this add-on strategy.
Referenced methods: C05: M03 §3.2.2–3.2.3; reverse-direction labeling and test adaptations are internally designed / H03: M19 §19.2.2–19.2.4, M03 §3.2.3; internal application / H05: Design considerations in M19 §19.2.2–19.2.4; detailed recording of confounding is internally designed / E02: M03 §3.2.3, M08 §8.2.2–8.2.3; internal application. Reason for adapting this to comparative HbA1c harm: needed to distinguish a common policy from a claim that everyone actually received identical concomitant medication. No new clinical causality/grade judgment or official methodological procedure was performed.

Related sources S01

N10 · Are the actual concomitant-treatment adjustments, adherence, rescue treatment and their analytical handling verified for each arm?

Current findings: The original record states that actual concomitant medications were not identical for everyone and that diabetes-medication adjustment was included in the comparison's care policy for the add-on strategy. The extent of changes by individual and arm, adherence to the target dose and detailed handling of rescue treatment were not verified.
Verification status: Partly verified
Materials actually read: Summary reading: the material at the exact identified location in the retained source summary was read. The linked external material was not read in this review.
Why unverified: Differences in concomitant treatment and permission to adjust treatment are verified, but the detailed data and analytical implications were not sufficiently verified.
Reason for missing information: Gaps remain in the extent and timing of actual medication changes by arm, adherence, and their detailed handling in the analytical model.
Required materials and conditions: Histories of changes to diabetes medications, statins and aspirin by arm, together with adherence, rescue-treatment and information on how these were handled in the analysis
Materials to obtain first: Histories of changes to diabetes medications, statins and aspirin by arm, together with adherence, rescue-treatment and information on how these were handled in the analysis
Further research: Compare actual treatment changes with the effect of interest for the add-on strategy, and examine how departures and adjustments by arm were handled in the analysis.
Remaining uncertainty: Gaps remain in the extent and timing of actual medication changes by arm, adherence, and their detailed handling in the analytical model. No new clinical effect, risk rate, individual response or grade is calculated or judged.
Conditions for verification: Actual data verify concomitant-medication changes, attainment of the target dose, adherence/discontinuation and the corresponding analytical handling for each arm.
Why this condition is needed: Needed to avoid turning the observed add-on strategy into an isolated drug contribution under completely fixed diabetes medication.
Application exceptions: The existence of a policy permitting changes does not establish that the extent of changes by arm, adherence or the adjustment model was also verified.
Referenced methods: H05: Design considerations in M19 §19.2.2–19.2.4; detailed recording of confounding is internally designed / E02: M03 §3.2.3, M08 §8.2.2–8.2.3; internal application / E04: M08 §8.2.2, M15 §15.3.1; internal application. Reason for adapting this to comparative HbA1c harm: needed to avoid turning the observed add-on strategy into an isolated drug contribution under completely fixed diabetes medication. No new clinical causality/grade judgment or official methodological procedure was performed.

Related sources S01

N11 · Are the actual methods for randomization, allocation concealment and baseline balance verified?

Current findings: ADVENT is a randomized, double-blind, matching-placebo-controlled parallel-group trial. Details of sequence generation and allocation concealment are recorded as unverified.
Verification status: Partly verified
Materials actually read: Summary reading: the material at the exact identified location in the retained source summary was read. The linked external material was not read in this review.
Why unverified: The design and reports of randomization/blinding are verified, but methodological details are lacking. Do not reuse the original B2 as a new bias judgment.
Reason for missing information: Details of sequence generation, allocation concealment and baseline balance for the selected comparison are needed.
Required materials and conditions: The original randomization-sequence and allocation-concealment procedures, and the baseline-characteristics table by arm
Materials to obtain first: The original randomization-sequence and allocation-concealment procedures, and the baseline-characteristics table by arm
Further research: Compare the allocation process with actual baseline balance, distinguishing verified methods from remaining gaps.
Remaining uncertainty: Details of sequence generation, allocation concealment and baseline balance for the selected comparison are needed. No new clinical effect, risk rate, individual response or grade is calculated or judged.
Conditions for verification: Material is available to verify the parallel-group design, random-sequence generation, allocation concealment and baseline balance.
Why this condition is needed: The labels RCT and double-blind alone cannot establish that sequence generation, concealment and selection differences have been addressed.
Application exceptions: Do not turn unverified concealment into actual absence of concealment or a confirmed bias defect. No new RoB grade is issued.
Referenced methods: E01: M08 §8.1–8.2.3; internal application / H05: Design considerations in M19 §19.2.2–19.2.4; detailed recording of confounding is internally designed. Reason for adapting this to comparative HbA1c harm: the labels RCT and double-blind alone cannot establish that sequence generation, concealment and selection differences have been addressed. No new clinical causality/grade judgment or official methodological procedure was performed.

Related sources S01

N12 · Are the definition, units, analysis time point and endpoint hierarchy for HbA1c verified?

Current findings: HbA1c is the original trial's primary (1st) safety endpoint and the current page's sole priority outcome. The outcome of interest is the between-group difference in change from baseline to week 16, in %p.
Verification status: Met
Materials actually read: Summary reading: the material at the exact identified location in the retained source summary was read. The linked external material was not read in this review.
Why unverified: The endpoint, hierarchy, time point and measure are verified in the retained original text. This status does not verify prospective agreement with the registration/SAP or an increase in clinical events.
Reason for missing information: The exact assay and comparison with prospective plans remain separately unverified.
Required materials and conditions: Material on the HbA1c outcome definition, units, time point and endpoint hierarchy, and their correspondence with the original plan
Materials to obtain first: Material on the HbA1c outcome definition, units, time point and endpoint hierarchy, and their correspondence with the original plan
Further research: Compare the selected outcome's change, between-group direction and hierarchy with the original results, and consider other endpoints separately.
Remaining uncertainty: The exact assay and comparison with prospective plans remain separately unverified. No new clinical effect, risk rate, individual response or grade is calculated or judged.
Conditions for verification: The between-group difference in change from baseline to week 16 in HbA1c, the %p unit, and its status as the original trial's primary (1st) safety endpoint are distinguished.
Why this condition is needed: Needed to avoid reading the primary (1st) safety endpoint, HbA1c, as a secondary lipid result, diagnostic event or incidence rate.
Application exceptions: Keep the reported primary (1st) hierarchy separate from whether its prospective registration plan has been verified.
Referenced methods: C06: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are internally designed / H01: M19 §19.1.2–19.2.4; detailed distinctions are internally designed / E03: M08 Table 8.2.a, M03 §3.2.4; internal application / E06: M08 Table 8.2.a, M04 §4.6.3; internal application. Reason for adapting this to comparative HbA1c harm: needed to avoid reading the primary (1st) safety endpoint, HbA1c, as a secondary lipid result, diagnostic event or incidence rate. No new clinical causality/grade judgment or official methodological procedure was performed.

Related sources S01

N13 · Are the actual laboratory measuring HbA1c and the scheduled visit times verified?

Current findings: HbA1c was scheduled to be assessed at the central laboratory at baseline and weeks 4·8·12·16. The denominators for actual completed measurements at each time point are unverified.
Verification status: Met
Materials actually read: Summary reading: the material at the exact identified location in the retained source summary was read. The linked external material was not read in this review.
Why unverified: The criterion for verifying the laboratory and schedule is met. This is not extended to verification of analysis denominators, assay standardization or handling of missing data.
Reason for missing information: Separate material is needed for completion denominators at each time point and the exact assay.
Required materials and conditions: The original testing schedule, laboratory and participant-specific records of completed measurements
Materials to obtain first: The original testing schedule, laboratory and participant-specific records of completed measurements
Further research: Link scheduled measurements with actual completion records and examine the denominator at each time point.
Remaining uncertainty: Separate material is needed for completion denominators at each time point and the exact assay. No new clinical effect, risk rate, individual response or grade is calculated or judged.
Conditions for verification: The original material specifies the central laboratory and measurements at baseline and weeks 4·8·12·16.
Why this condition is needed: Needed to distinguish repeated measurement time points from the single end-of-study outcome and clarify which follow-up period the result belongs to.
Application exceptions: Do not turn scheduled measurement times into a claim that completion/analysis data for every participant have been obtained.
Referenced methods: C06: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are internally designed / H01: M19 §19.1.2–19.2.4; detailed distinctions are internally designed / H02: Design-specific harm questions in M19 §19.2; details of temporal relationships are internally designed / E03: M08 Table 8.2.a, M03 §3.2.4; internal application. Reason for adapting this to comparative HbA1c harm: needed to distinguish repeated measurement time points from the single end-of-study outcome and clarify which follow-up period the result belongs to. No new clinical causality/grade judgment or official methodological procedure was performed.

Related sources S01

N14 · Are the HbA1c assay method, equipment, standardization and interference assessment verified?

Current findings: Beyond the information that a central laboratory was used, the exact HbA1c assay method, equipment, standardization and assay-interference assessment are unverified.
Verification status: Unverified
Materials actually read: Summary reading: the material at the exact identified location in the retained source summary was read. The linked external material was not read in this review.
Why unverified: Detailed specifications needed to compare the selected HbA1c difference with measurement conditions have not been obtained.
Reason for missing information: Direct original source locations for the assay method, equipment, standardization and interference assessment are unavailable.
Required materials and conditions: Specifications for the central laboratory's HbA1c method, equipment, standardization, quality control and interference assessment
Materials to obtain first: Specifications for the central laboratory's HbA1c method, equipment, standardization, quality control and interference assessment
Further research: Compare assay conditions with collection at each time point, and examine whether evidence of measurement differences or interference actually exists.
Remaining uncertainty: Direct original source locations for the assay method, equipment, standardization and interference assessment are unavailable. No new clinical effect, risk rate, individual response or grade is calculated or judged.
Conditions for verification: Material is available to verify the exact HbA1c method, equipment and standardization, and interference/measurement limitations by arm.
Why this condition is needed: The description of a central laboratory alone cannot guarantee measurement standardization or the absence of interference by arm.
Application exceptions: Do not turn unverified assay details into invalidity of the entire result or confirmation of assay interference.
Referenced methods: H01: M19 §19.1.2–19.2.4; detailed distinctions are internally designed / E03: M08 Table 8.2.a, M03 §3.2.4; internal application. Reason for adapting this to comparative HbA1c harm: the description of a central laboratory alone cannot guarantee measurement standardization or the absence of interference by arm. No new clinical causality/grade judgment or official methodological procedure was performed.

Related sources S01

N15 · Are the overall assigned/treated counts and selected-arm counts distinguished from the HbA1c analysis denominator?

Current findings: Overall, 148 participants were randomized; the authors' ITT/treated population, excluding those who received no treatment, comprised 146 participants. The selected-arm counts of 52/49 are not HbA1c analysis denominators. The structured field randomized_arm_counts=[52,49] is also retained under its original name.
Verification status: Met
Materials actually read: Summary reading: the material at the exact identified location in the retained source summary was read. The linked external material was not read in this review.
Why unverified: The retained manuscript clearly distinguishes each stage from the missing analysis n. This does not mean that the endpoint analysis denominator itself has been verified.
Reason for missing information: The HbA1c analysis n and the arm-specific links across stages are gaps addressed by the following condition.
Required materials and conditions: An arm-specific flow table for allocation, treatment, completion and endpoint analysis, and the original basis for the labels used
Materials to obtain first: An arm-specific flow table for allocation, treatment, completion and endpoint analysis, and the original basis for the labels used
Further research: Compare the stage represented by each sample count with the outcome denominator, and record the overall, selected, and analysis populations separately.
Remaining uncertainty: The HbA1c analysis n and the arm-specific links across stages are gaps addressed by the following condition. No new clinical effects, risk rates, individual responses, or grades are calculated or judged.
Conditions for verification: The overall counts of 148 assigned and 146 treated participants, the selected-arm counts of 52/49, and the unverified endpoint-specific analysis n are each explicitly distinguished.
Why this condition is needed: Needed to avoid substituting the overall sample or treated-arm counts for the analysis denominator of the selected HbA1c outcome.
Application exceptions: Preserve the original bytes of the structured group-count field name randomized_arm_counts and the manuscript's description of the treated groups; do not reinterpret them as the actual endpoint analysis n.
Referenced methods: C07: M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; adaptations for specific designs were developed internally / H06: M19 §19.1.2–19.2.4, M04 §4.6.3; internal application / E04: M08 §8.2.2, M15 §15.3.1; internal application. Reason for adapting this to the comparative HbA1c harm question: This is needed to avoid substituting the overall sample or treated-arm counts for the analysis denominator of the selected HbA1c outcome. No new clinical causality/grade judgment was made, and no official methodology was applied.

Related sources S01

N16 · Have the endpoint-specific HbA1c analysis n, handling of missing data, and variance of paired changes been verified?

Current findings: The HbA1c analysis n=[null,null], change SD=[null,null], and SE=null. Endpoint-specific handling of missing data and variance of paired changes are also unverified.
Verification status: Unverified
Materials actually read: Summary reading: the material at the exact identified location in the retained source summary was read. The linked external material was not read in this review.
Why unverified: The exact outcome denominators, missing-data information, and paired variances have not been obtained. The counts 52/49, 146, and 148 do not replace them.
Reason for missing information: Endpoint n, handling of missing data, and variance of paired changes are needed.
Required materials and conditions: Endpoint-specific n by arm, reasons for and handling of missing data, individual repeated measurements, and change-variance data
Materials to obtain first: Endpoint-specific n by arm, reasons for and handling of missing data, individual repeated measurements, and change-variance data
Further research: Compare the analysis populations, missing data at each time point, and variance of paired changes with the original results tables; do not fill unverified information through calculation.
Remaining uncertainty: Endpoint n, handling of missing data, and variance of paired changes are needed. No new clinical effects, risk rates, individual responses, or grades are calculated or judged.
Conditions for verification: The HbA1c analysis n, handling of missing data, and SD/SE of paired changes for the selected comparison are linked to original data.
Why this condition is needed: This is needed to avoid filling in analysis denominators, variances, or intervals from the selected-arm counts of 52/49 and a rounded P value.
Application exceptions: Preserve the original missing values. Do not substitute arm-specific end-of-study SEs for change SD/SE or perform new calculations.
Referenced methods: C07: M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; adaptations for specific designs were developed internally / H06: M19 §19.1.2–19.2.4, M04 §4.6.3; internal application / E04: M08 §8.2.2, M15 §15.3.1; internal application / E05: M15 §15.3.1–15.3.3; internal application. Reason for adapting this to the comparative HbA1c harm question: This is needed to avoid filling in analysis denominators, variances, or intervals from the selected-arm counts of 52/49 and a rounded P value. No new clinical causality/grade judgment was made, and no official methodology was applied.

Related sources S01

N17 · Have losses to follow-up, their reasons, and their effects on the endpoint been verified for the selected comparison?

Current findings: The original bias record retains attrition of 17/101=16.83% for the selected comparison. Detailed links between reasons/timing by arm and HbA1c missingness/handling are unverified.
Verification status: Partly verified
Materials actually read: Summary reading: the material at the exact identified location in the retained source summary was read. The linked external material was not read in this review.
Why unverified: Historical attrition figures are available, but endpoint missingness and analytical impact have not been verified. The existing B2 is not used as a score for the new review status.
Reason for missing information: Reasons by arm, timing, and the impact of endpoint missingness are unverified.
Required materials and conditions: A table linking reasons and timing of attrition/discontinuation by arm with HbA1c missingness and its handling
Materials to obtain first: A table linking reasons and timing of attrition/discontinuation by arm with HbA1c missingness and its handling
Further research: Track treatment discontinuation, loss to follow-up, and missing measurements separately to assess which data remain for the selected outcome.
Remaining uncertainty: Reasons by arm, timing, and the impact of endpoint missingness are unverified. No new clinical effects, risk rates, individual responses, or grades are calculated or judged.
Conditions for verification: Attrition counts, reasons by arm, timing, and their links to HbA1c missingness and its analytical impact are verified for the selected comparison.
Why this condition is needed: This is needed to avoid treating reported attrition and HbA1c missingness as the same event, or applying the original historical rate as a new bias score.
Application exceptions: The expression 17/101=16.83% is an existing record and is not recalculated. Original scoring criteria such as 15% or 200 participants are not imposed as adequacy criteria for the new conditions.
Referenced methods: C07: M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; adaptations for specific designs were developed internally / H06: M19 §19.1.2–19.2.4, M04 §4.6.3; internal application. Reason for adapting this to the comparative HbA1c harm question: This is needed to avoid treating reported attrition and HbA1c missingness as the same event, or applying the original historical rate as a new bias score. No new clinical causality/grade judgment was made, and no official methodology was applied.

Related sources S01

N18 · Does the authors' ITT designation agree with the actual effect of interest and analysis population?

Current findings: The authors describe the 146 treated participants as ITT but excluded participants who received no treatment. The selected HbA1c analysis n and exact model are unverified. The comparison is read as an add-on strategy under adjustable diabetes care.
Verification status: Partly verified
Materials actually read: Summary reading: the material at the exact identified location in the retained source summary was read. The linked external material was not read in this review.
Why unverified: The designation and exclusion of untreated participants are verified, but agreement with ITT based on all assigned participants and a formal between-group model cannot be established.
Reason for missing information: Details of inclusion/exclusion, the model, and the effect of interest for the endpoint analysis are needed.
Required materials and conditions: Analysis plan, inclusion/exclusion rules, between-group model, and definition of the effect of interest
Materials to obtain first: Analysis plan, inclusion/exclusion rules, between-group model, and definition of the effect of interest
Further research: Compare the authors' designation with the actual analysis population to distinguish the add-on strategy's effect of interest, adherence effects, and the effects of exclusions.
Remaining uncertainty: Details of inclusion/exclusion, the model, and the effect of interest for the endpoint analysis are needed. No new clinical effects, risk rates, individual responses, or grades are calculated or judged.
Conditions for verification: Agreement is verified between the effect of assignment overall or the actual effect of interest and the analysis inclusion/exclusion rules and model.
Why this condition is needed: This is needed to avoid treating a population that excludes untreated participants as ITT based on all randomized participants.
Application exceptions: Retain the authors' ITT wording while distinguishing it from actual exclusions and the effect of interest. Do not infer an adherence effect or an adjusted model.
Referenced methods: E04: M08 §8.2.2, M15 §15.3.1; internal application / H03: M19 §19.2.2–19.2.4, M03 §3.2.3; internal application / H06: M19 §19.1.2–19.2.4, M04 §4.6.3; internal application. Reason for adapting this to the comparative HbA1c harm question: This is needed to avoid treating a population that excludes untreated participants as ITT based on all randomized participants. No new clinical causality/grade judgment was made, and no official methodology was applied.

Related sources S01

N19 · Has attribution of the reported arm-specific HbA1c changes, P value, and existing arithmetic difference been verified?

Current findings: The arm-specific mean changes are +0.29 versus −0.02 %p, and the reported between-group P=0.048. The existing arithmetic difference of +0.31 %p remains designated reported_arm_changes_arithmetic_only; it is not a formal adjusted-model estimate.
Verification status: Met
Materials actually read: Summary reading: the material at the exact identified location in the retained source summary was read. The linked external material was not read in this review.
Why unverified: The sources and analytical nature of the reported values and existing arithmetic value are verified. This is not verification of the magnitude of clinical risk or a formal CI.
Reason for missing information: The formal between-group estimate, CI, and variance are gaps addressed by the following condition.
Required materials and conditions: Arm-specific mean changes, the reported between-group test, a formal model-estimate table, and the original arithmetic record
Materials to obtain first: Arm-specific mean changes, the reported between-group test, a formal model-estimate table, and the original arithmetic record
Further research: Link reported values to outcomes, time points, and analyses, distinguishing descriptive arithmetic from formal estimates without repeating the calculation.
Remaining uncertainty: The formal between-group estimate, CI, and variance are gaps addressed by the following condition. No new clinical effects, risk rates, individual responses, or grades are calculated or judged.
Conditions for verification: The selected comparison's +0.29 versus −0.02 %p, reported P=.048, and existing arithmetic +0.31 %p are each linked to their original locations and the nature of their analyses.
Why this condition is needed: This is needed to avoid turning the changes in both arms, the P value, and the arithmetic difference into different analyses or clinical risk rates.
Application exceptions: The original +0.31 %p is reused solely as historical arithmetic; no formal model estimate, formal CI, or individual risk rate is generated.
Referenced methods: C06: M03 §3.2.4, M15 §15.3.1–15.3.3; adaptations of outcomes to the specific question were developed internally / H03: M19 §19.2.2–19.2.4, M03 §3.2.3; internal application / E04: M08 §8.2.2, M15 §15.3.1; internal application. Reason for adapting this to the comparative HbA1c harm question: This is needed to avoid turning the changes in both arms, the P value, and the arithmetic difference into different analyses or clinical risk rates. No new clinical causality/grade judgment was made, and no official methodology was applied.

Related sources S01

N20 · Have the formal between-group HbA1c change estimate, SE, and CI been verified?

Current findings: The interval field and the standard error field (standard_error) in the retained calculation are null. A confidence interval for the formal between-group change estimate could not be verified from the original data, and +0.31 %p is only an arithmetic difference.
Verification status: Unverified
Materials actually read: Summary reading: the material at the exact identified location in the retained source summary was read. The linked external material was not read in this review.
Why unverified: The estimate, interval, and variance for the formal change contrast cannot be verified. Do not fill them in from the reported P value alone.
Reason for missing information: The formal estimate, SE/CI, and corresponding analysis/denominator are needed.
Required materials and conditions: A formal between-group change-estimate table, model, paired variance, denominator, and confidence interval
Materials to obtain first: A formal between-group change-estimate table, model, paired variance, denominator, and confidence interval
Further research: Link the formal estimate and interval to the verified analysis to examine compatible magnitudes, leaving unverified information unverified.
Remaining uncertainty: The formal estimate, SE/CI, and corresponding analysis/denominator are needed. No new clinical effects, risk rates, individual responses, or grades are calculated or judged.
Conditions for verification: The formal between-group change estimate and SE/CI appropriate to the selected comparison, time point, and analysis are verified from the original results.
Why this condition is needed: This is needed to avoid establishing the magnitude and precision of harm from significance or a simple mean difference alone.
Application exceptions: Do not reconstruct an interval or standardized effect using the rounded P=.048, end-of-study SEs, or 52/49.
Referenced methods: C07: M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; adaptations for specific designs were developed internally / E04: M08 §8.2.2, M15 §15.3.1; internal application / E05: M15 §15.3.1–15.3.3; internal application. Reason for adapting this to the comparative HbA1c harm question: This is needed to avoid establishing the magnitude and precision of harm from significance or a simple mean difference alone. No new clinical causality/grade judgment was made, and no official methodology was applied.

Related sources S01

N21 · Have the matching prospective registration, protocol, SAP, and handling of multiplicity been verified?

Current findings: The matching registration number, original protocol, and analysis plan are unverified, and registration_id and S01 nct are null. The exact multiplicity adjustment for the selected comparison has also not been verified.
Verification status: Unverified
Materials actually read: Summary reading: the material at the exact identified location in the retained source summary was read. The linked external material was not read in this review.
Why unverified: Insufficient material is available to verify comparison with the prospective plan and the handling of multiplicity. This does not mean that absence of registration or actual selective reporting has been established.
Reason for missing information: Planning, history, and multiplicity-handling information corresponding to ADVENT are needed.
Required materials and conditions: The matching ADVENT registration, original protocol, SAP, and information on analysis changes/multiplicity
Materials to obtain first: The matching ADVENT registration, original protocol, SAP, and information on analysis changes/multiplicity
Further research: Compare the prospective plan with the results by endpoint, time point, and analysis, leaving unobtained information unverified.
Remaining uncertainty: Planning, history, and multiplicity-handling information corresponding to ADVENT are needed. No new clinical effects, risk rates, individual responses, or grades are calculated or judged.
Conditions for verification: Agreement or changes in endpoints, time points, models, and multiplicity between the matching prospective ADVENT plan and actual results can be verified.
Why this condition is needed: This is needed to avoid treating a reported primary (1st) endpoint as completed verification against the planned analysis.
Application exceptions: A null registration_id and an unobtained plan do not establish that the study was unregistered or selectively reported. Do not attach another registration or protocol to ADVENT.
Referenced methods: C09: M04 §4.5, §4.6.3; the limits of the current data conversion follow the user-defined scope and internal design / E06: M08 Table 8.2.a, M04 §4.6.3; internal application. Reason for adapting this to the comparative HbA1c harm question: This is needed to avoid treating a reported primary (1st) endpoint as completed verification against the planned analysis. No new clinical causality/grade judgment was made, and no official methodology was applied.

Related sources S01

N22 · Has a validated threshold for the clinical importance of this HbA1c difference been identified?

Current findings: An increase signal exists, but its clinical magnitude could not be judged because a validated clinical-importance threshold, variance of paired changes, and formal interval are unavailable. The original EX means that clinical magnitude remains undetermined.
Verification status: Unverified
Materials actually read: Summary reading: the material at the exact identified location in the retained source summary was read. The linked external material was not read in this review.
Why unverified: A justified importance threshold and corresponding statistical information are lacking. The original P value and arithmetic +0.31 %p alone do not establish the magnitude of important harm.
Reason for missing information: Context-specific evidence on importance, paired variance, and a formal interval are needed.
Required materials and conditions: A validated importance threshold, paired variance, and patient-importance information for this HbA1c comparison
Materials to obtain first: A validated importance threshold, paired variance, and patient-importance information for this HbA1c comparison
Further research: Interpret verified evidence on importance against the formal change estimate/interval; do not replace an importance threshold with conventional significance alone.
Remaining uncertainty: Context-specific evidence on importance, paired variance, and a formal interval are needed. No new clinical effects, risk rates, individual responses, or grades are calculated or judged.
Conditions for verification: An important-difference threshold or a justified interpretation of the corresponding standardized effect appropriate to this population, add-on strategy, and duration is verified.
Why this condition is needed: This is needed to distinguish an increase signal from the magnitude of clinically important deterioration.
Application exceptions: Do not turn EX into no numerical value, no effect, or failure to meet a threshold, and do not invent an arbitrary MCID, minimum n, or duration.
Referenced methods: E05: M15 §15.3.1–15.3.3; internal application / H09: Chamgap's own interpretive boundaries. The M19 principles are referenced; no official causality tool was applied. Reason for adapting this to the comparative HbA1c harm question: This is needed to distinguish an increase signal from the magnitude of clinically important deterioration. No new clinical causality/grade judgment was made, and no official methodology was applied.

Related sources S01

N23 · For the 1,000 mg arm in the same ADVENT trial, have the HbA1c difference and uncertainty been verified?

Current findings: The 1,000 mg/day arm in the same ADVENT trial did not establish a significant difference from placebo, with P=0.16. It is not counted as independent replication, and the current retained summary lacks the complete difference, denominator, and CI for that comparison.
Verification status: Partly verified
Materials actually read: Summary reading: the material at the exact identified location in the retained source summary was read. The linked external material was not read in this review.
Why unverified: The report of a nonsignificant test is verified, but the full between-group effect magnitude and uncertainty have not been verified.
Reason for missing information: Complete results, denominators, and a formal interval for that dose arm are needed.
Required materials and conditions: The 1,000 mg arm's HbA1c results, between-group estimate/interval, and denominator in the same trial
Materials to obtain first: The 1,000 mg arm's HbA1c results, between-group estimate/interval, and denominator in the same trial
Further research: Compare the actual results and analyses by dose, retaining them as context from the same family; do not newly calculate direct dose effects or a harmless-dose threshold.
Remaining uncertainty: Complete results, denominators, and a formal interval for that dose arm are needed. No new clinical effects, risk rates, individual responses, or grades are calculated or judged.
Conditions for verification: For the 1,000 mg arm, the actual between-group HbA1c difference, denominator, and interval are verified and distinguished from the selected 1,500 mg comparison.
Why this condition is needed: This is needed to avoid turning another dose in the same trial into independent replication or evidence of safety at all lower doses.
Application exceptions: Do not interpret nonsignificance at P=.16 as an effect of 0, equivalence, a harmless dose, or an established dose–response relationship.
Referenced methods: C08: M04 §4.6.3, M15 §15.3.1–15.3.3; separation of statuses was developed internally / E07: M04 §4.6.1–4.6.2, M15 §15.3.1; internal application / E08: M03 §3.2.1–3.2.4; details of dose, persistence, and effect modification were developed internally / H07: M04 §4.6.1–4.6.2; adaptation for harm data was developed internally. Reason for adapting this to the comparative HbA1c harm question: This is needed to avoid turning another dose in the same trial into independent replication or evidence of safety at all lower doses. No new clinical causality/grade judgment was made, and no official methodology was applied.

Related sources S01

N24 · For the 1,000 mg arm, does baseline HbA1c agree between the table and abstract?

Current findings: For the same 1,000 mg arm, baseline HbA1c is recorded as 7.23% in the table and 7.28% in the abstract; it was not arbitrarily corrected.
Verification status: Conflicting information
Materials actually read: Summary reading: the material at the exact identified location in the retained source summary was read. The linked external material was not read in this review.
Why unverified: Reports of the same baseline value actually disagree. Successful preservation of the conflict is distinguished from verification of data consistency.
Reason for missing information: An original correction, author explanation, or additional context distinguishing the values is needed.
Required materials and conditions: The corresponding value in the original Table 1 and abstract, and any correction or author explanation
Materials to obtain first: The corresponding value in the original Table 1 and abstract, and any correction or author explanation
Further research: Compare the original locations for the same fact side by side; resolve differences only when correction evidence is available, retaining the previous values.
Remaining uncertainty: An original correction, author explanation, or additional context distinguishing the values is needed. No new clinical effects, risk rates, individual responses, or grades are calculated or judged.
Conditions for verification: For the same 1,000 mg arm, baseline HbA1c agrees between the table and abstract, or the difference is resolved by evidence of a correction.
Why this condition is needed: This is needed to avoid arbitrarily correcting conflicting values or claiming that they have been reconciled as different endpoints.
Application exceptions: Do not treat successful documentation of a conflict as fulfillment of the data-consistency condition. Do not change values for the currently selected arms.
Referenced methods: C08: M04 §4.6.3, M15 §15.3.1–15.3.3; separation of statuses was developed internally / E03: M08 Table 8.2.a, M03 §3.2.4; internal application. Reason for adapting this to the comparative HbA1c harm question: This is needed to avoid arbitrarily correcting conflicting values or claiming that they have been reconciled as different endpoints. No new clinical causality/grade judgment was made, and no official methodology was applied.

Related sources S01

N25 · Has the original material for the no-change conference presentation cited by the study report been verified?

Current findings: The original study report states that a conference presentation found no HbA1c change. That original presentation could not be directly verified, and the 13 bibliographic records (citation) do not contain a separate presentation identity.
Verification status: Unverified
Materials actually read: Summary reading: the material at the exact identified location in the retained source summary was read. The linked external material was not read in this review.
Why unverified: The included document contains a secondhand citation, but the actual material, family, and results of the original presentation have not been verified.
Reason for missing information: The identity and content of the original presentation and its family links are needed.
Required materials and conditions: The original conference abstract, presentation identity, population/intervention, results, and trial-linkage information
Materials to obtain first: The original conference abstract, presentation identity, population/intervention, results, and trial-linkage information
Further research: Verify the relationship between the original presentation and study report to distinguish same-family, different-family, and unknown relationships; do not count a secondhand citation as independent replication.
Remaining uncertainty: The identity and content of the original presentation and its family links are needed. No new clinical effects, risk rates, individual responses, or grades are calculated or judged.
Conditions for verification: Material is available to directly verify the identity, population, intervention, HbA1c results, and family relationships of the original presentation.
Why this condition is needed: This is needed to avoid elevating the study report's secondhand citation to a newly read independent presentation result.
Application exceptions: Do not assign a unique trial count or participant count to a presentation whose relationship to the same trial or another family is unverified.
Referenced methods: C02: M04 §4.6.1–4.6.2: distinction between studies and reports; internal application to cohort/outcome linkage / C03: M04 §4.5–4.6: data-collection/selection principles; the distinction between access and reading and the hyperlink conventions were developed internally / C08: M04 §4.6.3, M15 §15.3.1–15.3.3; separation of statuses was developed internally / H07: M04 §4.6.1–4.6.2; adaptation for harm data was developed internally. Reason for adapting this to the comparative HbA1c harm question: This is needed to avoid elevating the study report's secondhand citation to a newly read independent presentation result. No new clinical causality/grade judgment was made, and no official methodology was applied.

Related sources S01

N26 · Have the actual formulation, comparison, timing, and between-group HbA1c results of ADMIT been verified?

Current findings: ADMIT compares a different IR Niacor formulation, dose, run-in, factorial co-interventions, and population/time-specific effect of interest. HbA1c was maintained within the nicotinic acid arm, while it declined in the placebo arm. The original record also preserves an abstract/table P-value discrepancy, but the current retained summary does not contain the specific figures.
Verification status: Partly verified
Materials actually read: Summary reading: the material at the exact identified location in the retained source summary was read. The linked external material was not read in this review.
Why unverified: The direction and design differences of the indirect comparison are verified, but the complete between-group estimate, denominator, uncertainty, and details of the P-value conflict are lacking.
Reason for missing information: The complete ADMIT results tables, denominators, and original locations of the test discrepancy are needed.
Required materials and conditions: ADMIT treatment/run-in, factorial co-interventions, diabetic-subgroup results tables, denominators, tests/intervals, and corrections
Materials to obtain first: ADMIT treatment/run-in, factorial co-interventions, diabetic-subgroup results tables, denominators, tests/intervals, and corrections
Further research: Compare formulation, population, co-interventions, and the effect of interest over time to distinguish within-arm from between-arm results; do not count them together as direct ER comparisons.
Remaining uncertainty: The complete ADMIT results tables, denominators, and original locations of the test discrepancy are needed. No new clinical effects, risk rates, individual responses, or grades are calculated or judged.
Conditions for verification: The IR formulation, different dose/run-in/population, time point of interest, between-group results, and uncertainty in ADMIT are verified.
Why this condition is needed: This is needed to avoid turning within-arm maintenance in IR ADMIT into a null between-group effect for NIASPAN ER or replication of the exact comparison.
Application exceptions: Retain the ADMIT abstract/table P-value discrepancy as originally recorded; do not newly fill in figures absent from the current retained version.
Referenced methods: C05: M03 §3.2.2–3.2.3; reverse-direction labeling and test adaptations were developed internally / C06: M03 §3.2.4, M15 §15.3.1–15.3.3; adaptations of outcomes to the specific question were developed internally / C08: M04 §4.6.3, M15 §15.3.1–15.3.3; separation of statuses was developed internally / E04: M08 §8.2.2, M15 §15.3.1; internal application / E07: M04 §4.6.1–4.6.2, M15 §15.3.1; internal application / H03: M19 §19.2.2–19.2.4, M03 §3.2.3; internal application. Reason for adapting this to the comparative HbA1c harm question: This is needed to avoid turning within-arm maintenance in IR ADMIT into a null between-group effect for NIASPAN ER or replication of the exact comparison. No new clinical causality/grade judgment was made, and no official methodology was applied.

Related sources S02

N27 · Have the actual release formulation, measurements, and period-specific contrasts in the Garg crossover trial been verified?

Current findings: The PubMed abstract record describes a 13-participant crossover trial, 1 dose of 1.5 g taken three times daily, 8 weeks per period, and a relative increase in glycosylated hemoglobin. The release formulation and equivalence to the selected HbA1c assay are unverified.
Verification status: Partly verified
Materials actually read: Summary reading: the material at the exact identified location in the retained source summary was read. The linked external material was not read in this review.
Why unverified: Abstract-level information on design, administration, and direction is available, but the formulation, assay equivalence, and complete paired analysis have not been verified.
Reason for missing information: The release formulation, assay method, crossover analysis, and formal results in the original full text are needed.
Required materials and conditions: The product release formulation, assay method, crossover sequence/periods, paired results, and denominators in the original Garg full text
Materials to obtain first: The product release formulation, assay method, crossover sequence/periods, paired results, and denominators in the original Garg full text
Further research: Examine the actual periods and paired contrasts in the crossover design and assay equivalence; do not calculate an independent-arm effect.
Remaining uncertainty: The release formulation, assay method, crossover analysis, and formal results in the original full text are needed. No new clinical effects, risk rates, individual responses, or grades are calculated or judged.
Conditions for verification: The crossover trial's release formulation, measurement method, paired period comparison, and denominator/interval are verified.
Why this condition is needed: This is needed to avoid automatically equating the nicotinic acid name and glycosylated hemoglobin results with the selected ER HbA1c change.
Application exceptions: Do not calculate the 13-participant crossover trial as an independent-arm design or treat glycosylated hemoglobin as a verified equivalent HbA1c assay.
Referenced methods: C05: M03 §3.2.2–3.2.3; reverse-direction labeling and test adaptations were developed internally / C06: M03 §3.2.4, M15 §15.3.1–15.3.3; adaptations of outcomes to the specific question were developed internally / C07: M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; adaptations for specific designs were developed internally / E04: M08 §8.2.2, M15 §15.3.1; internal application / E07: M04 §4.6.1–4.6.2, M15 §15.3.1; internal application / H03: M19 §19.2.2–19.2.4, M03 §3.2.3; internal application. Reason for adapting this to the comparative HbA1c harm question: This is needed to avoid automatically equating the nicotinic acid name and glycosylated hemoglobin results with the selected ER HbA1c change. No new clinical causality/grade judgment was made, and no official methodology was applied.

Related sources S03

N28 · Have the ingredient, product, and comparison in the report of improvement with low-dose niacin and sitagliptin been verified?

Current findings: The study of low-dose niacin 14 mg/day combined with sitagliptin reported improvement. The exact nicotinic acid/amide identity and product, including its release formulation, are unverified, and this differs from the NIASPAN ER 1,500 mg/day comparison.
Verification status: Partly verified
Materials actually read: Summary reading: the material at the exact identified location in the retained source summary was read. The linked external material was not read in this review.
Why unverified: The favorable direction and the difference in low-dose co-treatment are verified, but the actual ingredient, product, and complete comparative estimate have not been sufficiently verified.
Reason for missing information: The exact molecule, product, arm composition, and results tables are needed.
Required materials and conditions: Ingredient/product specifications, sitagliptin/chromium arm composition, comparator, and HbA1c results tables for the Karim trial
Materials to obtain first: Ingredient/product specifications, sitagliptin/chromium arm composition, comparator, and HbA1c results tables for the Karim trial
Further research: Compare the molecule, product, co-treatment, comparator, and direction of results, preserving them separately from the selected comparison.
Remaining uncertainty: The exact molecule, product, arm composition, and results tables are needed. No new clinical effects, risk rates, individual responses, or grades are calculated or judged.
Conditions for verification: The actual molecule, product, dose, co-treatment arms, comparator, and comparative scope of the HbA1c results are verified.
Why this condition is needed: This is needed to retain results in the opposite direction while preventing findings with a different dose and co-treatment from being repurposed for the selected prescription ER comparison.
Application exceptions: Do not fill in NIASPAN for the unverified nicotinic acid/amide identity and product of the 14 mg/day niacin.
Referenced methods: C05: M03 §3.2.2–3.2.3; reverse-direction labeling and test adaptations were developed internally / C06: M03 §3.2.4, M15 §15.3.1–15.3.3; adaptations of outcomes to the specific question were developed internally / C08: M04 §4.6.3, M15 §15.3.1–15.3.3; separation of statuses was developed internally / E02: M03 §3.2.3, M08 §8.2.2–8.2.3; internal application / E07: M04 §4.6.1–4.6.2, M15 §15.3.1; internal application / H03: M19 §19.2.2–19.2.4, M03 §3.2.3; internal application. Reason for adapting this to the comparative HbA1c harm question: This is needed to retain results in the opposite direction while preventing findings with a different dose and co-treatment from being repurposed for the selected prescription ER comparison. No new clinical causality/grade judgment was made, and no official methodology was applied.

Related sources S04

N29 · Has evidence of independent replication of the exact NIASPAN comparison been verified?

Current findings: The direct core evidence (evidence_core) consists only of ADVENT-2002. Other doses, abstracts/secondhand citations, and regulatory summaries from the same trial are not independent replication, and independent replication of the exact comparison was not verified in the current retained material.
Verification status: Unverified
Materials actually read: Summary reading: the material at the exact identified location in the retained source summary was read. The linked external material was not read in this review.
Why unverified: No material is available to verify independent replication of the exact comparison. Do not turn the 13 bibliographic records (citation) or reports from the same family into a replication count.
Reason for missing information: Independent results for the exact comparison and family-linkage material are needed.
Required materials and conditions: Links between unique trials and reports, and independent results tables, for the exact comparison
Materials to obtain first: Links between unique trials and reports, and independent results tables, for the exact comparison
Further research: Link reports to trial families, endpoints, and analyses to distinguish same, different, and unknown relationships; leave the undetermined number of unique studies without a value.
Remaining uncertainty: Independent results for the exact comparison and family-linkage material are needed. No new clinical effects, risk rates, individual responses, or grades are calculated or judged.
Conditions for verification: Results from an independent family matching the product, dose, population, policy, time point, and HbA1c comparison are directly verified.
Why this condition is needed: This is needed to avoid counting reports of the same dose arms, regulatory secondhand citations, reviews, or registrations as independent replication trials.
Application exceptions: Preserve the original R1 and the single direct family. Do not newly judge the number of studies worldwide, the total number of unique participants, or the absence of replication.
Referenced methods: C02: M04 §4.6.1–4.6.2: distinction between studies and reports; internal application to cohort/outcome linkage / E07: M04 §4.6.1–4.6.2, M15 §15.3.1; internal application / H07: M04 §4.6.1–4.6.2; adaptation for harm data was developed internally. Reason for adapting this to the comparative HbA1c harm question: This is needed to avoid counting reports of the same dose arms, regulatory secondhand citations, reviews, or registrations as independent replication trials. No new clinical causality/grade judgment was made, and no official methodology was applied.

Related sources S01

N30 · Have funding, manufacturer-affiliated authors, and disclosed conflicts of interest in the direct trial been verified?

Current findings: ADVENT records Kos support, manufacturer-affiliated authors, and disclosed speaking/stock relationships. The original I0 is this historical classification and is not used as a new deduction under the criteria.
Verification status: Met
Materials actually read: Summary reading: the material at the exact identified location in the retained source summary was read. The linked external material was not read in this review.
Why unverified: The reported funding and author relationships in the direct trial are verified. This does not mean that independent replication has been verified or the actual magnitude of bias has been calculated.
Reason for missing information: Relationships beyond the disclosed scope and separate independent replication of the exact comparison have not been verified.
Required materials and conditions: Original funding information, author affiliations, product supply, speaking/stock/employment relationships, and COI disclosures
Materials to obtain first: Original funding information, author affiliations, product supply, speaking/stock/employment relationships, and COI disclosures
Further research: Distinguish and verify each source of funding, employment relationship, and disclosure, and examine the scope of claims of independence.
Remaining uncertainty: Relationships beyond the disclosed scope and separate independent replication of the exact comparison have not been verified. No new clinical effects, risk rates, individual responses, or grades are calculated or judged.
Conditions for verification: Funding, author affiliations, and disclosed relationships such as speaking/stock interests in the core trial are linked to their original locations.
Why this condition is needed: This is needed to avoid penalizing manufacturer support/author relationships again as trial-method bias, or automatically deleting the data.
Application exceptions: The presence of Kos support is not used to declare the figures invalid, nor as proof of independent funding or independent replication.
Referenced methods: C10: Chamgap's own criteria for independence and attribution. The official methodological sections used in this pilot do not warrant all of these detailed items. Reason for adapting this to the comparative HbA1c harm question: This is needed to avoid penalizing manufacturer support/author relationships again as trial-method bias, or automatically deleting the data. No new clinical causality/grade judgment was made, and no official methodology was applied.

Related sources S01

N31 · Can the products and versions in the official ER documents, and their differences from the historical trial, be verified?

Current findings: S05 is the AvPAK/AvKARE generic niacin ER label updated 2026-02-25 and revised 2/2026. S06 reuses the historical file of the 2020 NIASPAN PDF. Neither substitutes for evidence of the original trial's manufacturing batch, titration schedule, or HbA1c effect.
Verification status: Met
Materials actually read: Summary reading: the material at the exact identified location in the retained source summary was read. The linked external material was not read in this review.
Why unverified: The distinctions among products, versions, and roles in the retained bibliography and records are verified. This does not verify current web responses or currency as of 2026-10-05.
Reason for missing information: No check of current version updates or actual access responses was attempted in this review; detailed trial manufacturing information remains a separate gap.
Required materials and conditions: Products, versions, dates, description/warning sections in the DailyMed/FDA documents, and information linking them to the trial product
Materials to obtain first: Products, versions, dates, description/warning sections in the DailyMed/FDA documents, and information linking them to the trial product
Further research: Compare official documents by version, product, and date to distinguish exposure in the historical trial from the safety background.
Remaining uncertainty: No check of current version updates or actual access responses was attempted in this review; detailed trial manufacturing information remains a separate gap. No new clinical effects, risk rates, individual responses, or grades are calculated or judged.
Conditions for verification: The products, versions, and review scope of the official generic document available at the reference date and the historical NIASPAN document are distinguished.
Why this condition is needed: Needed to avoid automatically treating the 2026 generic label and the 2020 NIASPAN file as manufacturing details for the original trial, the latest documents, or estimates of the trial effect.
Application exceptions: The current official webpages/PDFs are not newly read, and their currency or jurisdiction-specific approvals are not rechecked.
Referenced methods: C05: M03 §3.2.2–3.2.3; reverse-direction labeling and test adaptations are internally designed / C09: M04 §4.5, §4.6.3; the limits of the current data conversion follow the user-defined scope and internal design / H08: M19 §19.1.2–19.2.4; internal application / E10: M19 §19.1.2–19.2.4; internal application. Reason for adaptation to the comparative HbA1c harm question: needed to avoid automatically treating the 2026 generic label and the 2020 NIASPAN file as manufacturing details for the original trial, the latest documents, or estimates of the trial effect. No new clinical causality/grade judgment or application of an official method was performed.

Related sources S05 S06

N32 · Can the collection of other harms, discontinuations, and exposure denominators in the same trial be verified?

Current findings: The original safety wording states that failure to detect major liver or muscle events in the short trial does not guarantee long-term safety. Official ER warnings cover glucose, liver, urate/gout, flushing, and muscle harms with statin co-treatment. The current retained summary does not contain complete information on collection of other AEs or group-specific events/denominators in the selected trial.
Verification status: Partly verified
Materials actually read: Summary reading: the material at the exact identified location in the retained source summary was read. The linked external material was not read in this review.
Why unverified: The retained warnings and limited short-term observations are verified, but complete group-specific AE collection, denominators, and discontinuations have not been verified.
Reason for missing information: Systematic collection and group-specific exposure/event/discontinuation data for separate AEs are needed.
Required materials and conditions: Trial AE definitions, collection procedures, group-specific exposure/events/discontinuations, duration data, and original locations of official warnings
Materials to obtain first: Trial AE definitions, collection procedures, group-specific exposure/events/discontinuations, duration data, and original locations of official warnings
Further research: Distinguish continuous HbA1c changes from separate AEs when comparing collection, exposure denominators, and person/event counts; do not fill unreported information with 0.
Remaining uncertainty: Systematic collection and group-specific exposure/event/discontinuation data for separate AEs are needed. No new clinical effects, risk rates, individual responses, or grades are calculated or judged.
Conditions for verification: Definitions, collection, group-specific person/event counts, durations, and discontinuations for other AEs in the same population under the same exposure are verified.
Why this condition is needed: Needed to avoid turning the failure to detect major liver or muscle events in a short trial, together with official warnings, into an event rate of 0 or overall safety.
Application exceptions: H04 is adapted only to data requirements for the frequency of separate events, such as liver/muscle events; it is not imposed as a mandatory incidence requirement for the continuous mean change in HbA1c.
Referenced methods: H01: M19 §19.1.2–19.2.4; detailed distinctions are internally designed / H04: M19 §19.1.2–19.2.4; internal application / H06: M19 §19.1.2–19.2.4, M04 §4.6.3; internal application / E10: M19 §19.1.2–19.2.4; internal application. Reason for adaptation to the comparative HbA1c harm question: needed to avoid turning the failure to detect major liver or muscle events in a short trial, together with official warnings, into an event rate of 0 or overall safety. No new clinical causality/grade judgment or application of an official method was performed.

Related sources S01 S05 S06

N33 · Can data on persistent HbA1c effects, long-term complications, and rare harms be verified?

Current findings: Long-term follow-up for the selected question has no value (null), and the original list of unverified matters (unknowns) states that the short-term design cannot determine the magnitude of persistent HbA1c effects, long-term complications, or rare harms.
Verification status: Unverified
Materials actually read: Summary reading: the material at the exact identified location in the retained source summary was read. The linked external material was not read in this review.
Why unverified: The core design did not investigate the long-term scope, and no verified data are available. This is neither a reason to delete the selected 16-week result nor a claim that no studies exist worldwide.
Reason for missing information: Direct data on long-term and rare harms for the selected exposure and population are needed.
Required materials and conditions: Exposure/follow-up data on HbA1c after discontinuation, long-term complications, rare events, and vulnerable groups
Materials to obtain first: Exposure/follow-up data on HbA1c after discontinuation, long-term complications, rare events, and vulnerable groups
Further research: Distinguish long-term follow-up, repeated-measurement, and event-collection methods suited to the question; do not interpret short-term nondetection as long-term safety.
Remaining uncertainty: Direct data on long-term and rare harms for the selected exposure and population are needed. No new clinical effects, risk rates, individual responses, or grades are calculated or judged.
Conditions for verification: Appropriate follow-up data are available to verify persistent/long-term and rare harms for the selected population and product.
Why this condition is needed: Needed to avoid establishing persistent effects, rare events, or risks in excluded vulnerable groups from short-term mean changes.
Application exceptions: Not every long-term study is unconditionally required to answer the narrow 16-week HbA1c claim, but gaps in extended claims remain explicit.
Referenced methods: H08: M19 §19.1.2–19.2.4; internal application / E08: M03 §3.2.1–3.2.4; details of dose, persistence, and effect modification are internally designed. Reason for adaptation to the comparative HbA1c harm question: needed to avoid establishing persistent effects, rare events, or risks in excluded vulnerable groups from short-term mean changes. No new clinical causality/grade judgment or application of an official method was performed.

Related sources S01

N34 · Can the body text, results, and correspondence to ADVENT of the registry leads be verified?

Current findings: DRKS concerns a different intestinal-release product in healthy/prediabetic participants, and its HbA1c screening range is not a result. Historical access to the official NCT00108485 body text yielded a JS shell/API failure, with only a termination lead from a mirror available. The official NCT06378125 body text also yielded only a shell historically, and its cross-link to DRKS is unverified.
Verification status: Partly verified
Materials actually read: Summary reading: the material at the exact identified location in the retained source summary was read. The linked external material was not read in this review.
Why unverified: Some registry identities, different populations/products, and historical access limits are verified, but official results, reasons for termination, and correspondence among registrations have not been verified.
Reason for missing information: Materials directly verifying official body text/history, results, and registry links are needed.
Required materials and conditions: Official body text/history, results, and verified linkage data for DRKS00030865, NCT00108485, and NCT06378125
Materials to obtain first: Official body text/history, results, and verified linkage data for DRKS00030865, NCT00108485, and NCT06378125
Further research: Compare each registration's population, release product, endpoints, results, and links to distinguish plans/status/mirror leads from clinical results.
Remaining uncertainty: Materials directly verifying official body text/history, results, and registry links are needed. No new clinical effects, risk rates, individual responses, or grades are calculated or judged.
Conditions for verification: The official body text, results, registry links, and correspondence to the selected ADVENT comparison are directly verified.
Why this condition is needed: Needed to avoid elevating registry completion/termination status, mirrors, or a JS shell to verified HbA1c results or replication of ADVENT.
Application exceptions: Do not assert that NCT06378125 and DRKS00030865 are the same registration without a verified cross-link. Do not display historical access failures as current failures.
Referenced methods: C02: the distinction between studies and reports in M04 §4.6.1–4.6.2; internal application to cohort/outcome linkage / C03: the data-collection/selection principles in M04 §4.5–4.6; the distinction between access and reading, and the hyperlink conventions, are internally designed / C09: M04 §4.5, §4.6.3; the limits of the current data conversion follow the user-defined scope and internal design / E06: M08 Table 8.2.a, M04 §4.6.3; internal application / H07: M04 §4.6.1–4.6.2; adaptation for harm data is internally designed. Reason for adaptation to the comparative HbA1c harm question: needed to avoid elevating registry completion/termination status, mirrors, or a JS shell to verified HbA1c results or replication of ADVENT. No new clinical causality/grade judgment or application of an official method was performed.

Related sources S07 S08 S09 S10

N35 · Can the actual body text, scope, and family relationships of the review, protocol, and expression-of-concern notice be verified?

Current findings: S11 was used only for discovery/cross-checking through bibliographic records and access-failure records; no pooled figures were adopted. S12 is an indexed protocol, not results. S13 is an indexed lead concerning that protocol; its body text and precise scope could not be read. This lead was not used as evidence against ADVENT.
Verification status: Partly verified
Materials actually read: Summary reading: the material at the exact identified location in the retained source summary was read. The linked external material was not read in this review.
Why unverified: Document types and linkage leads are available, but the actual details of the review content, protocol, and notice text have not been verified.
Reason for missing information: Actual body text, scope, included trials, and official document links are needed.
Required materials and conditions: The review's included trials/results tables, protocol body text, content/scope of the expression-of-concern notice, and document links
Materials to obtain first: The review's included trials/results tables, protocol body text, content/scope of the expression-of-concern notice, and document links
Further research: Distinguish results, plans, and editorial notices, attributing them only to the corresponding documents; do not count them as independent trials or extend them to unrelated trials.
Remaining uncertainty: Actual body text, scope, included trials, and official document links are needed. No new clinical effects, risk rates, individual responses, or grades are calculated or judged.
Conditions for verification: The actual content of the S11 included trials, S12 plans, and S13 notice, and their relationships to the corresponding documents/trials, are verified.
Why this condition is needed: Needed to avoid repurposing the existence of a review, an indexed protocol, or an expression-of-concern lead as confirmation of results or evidence of an ADVENT defect.
Application exceptions: Keep the spelling in the actual returned S13 link byte-for-byte. Do not add scope or ADVENT relevance without having read the original text of the expression-of-concern notice.
Referenced methods: C02: the distinction between studies and reports in M04 §4.6.1–4.6.2; internal application to cohort/outcome linkage / C03: the data-collection/selection principles in M04 §4.5–4.6; the distinction between access and reading, and the hyperlink conventions, are internally designed / C08: M04 §4.6.3, M15 §15.3.1–15.3.3; separation of statuses is internally designed / C09: M04 §4.5, §4.6.3; the limits of the current data conversion follow the user-defined scope and internal design / E06: M08 Table 8.2.a, M04 §4.6.3; internal application / H07: M04 §4.6.1–4.6.2; adaptation for harm data is internally designed. Reason for adaptation to the comparative HbA1c harm question: needed to avoid repurposing the existence of a review, an indexed protocol, or an expression-of-concern lead as confirmation of results or evidence of an ADVENT defect. No new clinical causality/grade judgment or application of an official method was performed.

Related sources S11 S12 S13

N36 · Does this HbA1c comparison also answer questions about incident diabetes or cardiovascular/complication events?

Current findings: Fasting glucose, incident diabetes, lipids, FMD, and cardiovascular events are not substitute endpoints for the selected HbA1c success criterion. The current HbA1c increase does not establish differences in long-term complications or cardiovascular events.
Verification status: Unverified
Materials actually read: Summary reading: the material at the exact identified location in the retained source summary was read. The linked external material was not read in this review.
Why unverified: The selected material addresses the HbA1c comparison; this table has no material for verifying direct estimates of those clinical events.
Reason for missing information: If separate clinical events are asked about, direct event results, denominators, and follow-up are needed.
Required materials and conditions: Definitions, denominators, follow-up, and between-group results for incident diabetes and cardiovascular/complication events in the selected comparison
Materials to obtain first: Definitions, denominators, follow-up, and between-group results for incident diabetes and cardiovascular/complication events in the selected comparison
Further research: Review appropriate follow-up that measures and analyzes HbA1c and event endpoints separately, and do not estimate event effects from the surrogate alone.
Remaining uncertainty: If separate clinical events are asked about, direct event results, denominators, and follow-up are needed. No new clinical effects, risk rates, individual responses, or grades are calculated or judged.
Conditions for verification: Direct results are available to address the separate clinical-event question in the same population with the same product and comparison.
Why this condition is needed: Needed to avoid treating a mean difference in a surrogate as an increase in event incidence or long-term complications.
Application exceptions: Because the original question concerns HbA1c change itself, event trials are not imposed as an invariably mandatory condition for verifying that result.
Referenced methods: C06: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are internally designed / E09: M03 §3.2.4; internally defined extension boundaries / H08: M19 §19.1.2–19.2.4; internal application / H09: Chamgap's own interpretive boundaries. The M19 principles are referenced; no official causality tool was applied. Reason for adaptation to the comparative HbA1c harm question: needed to avoid treating a mean difference in a surrogate as an increase in event incidence or long-term complications. No new clinical causality/grade judgment or application of an official method was performed.

Related sources S01

N37 · Are current summary reading, each material's historical access/access date, and current external nonreading distinguished?

Current findings: In this review, the complete KO/EN text, evidence, and bibliography in the current retained source summary were read. The 13 bibliographic records (citation) have access_date=2026-09-15 and different historical access levels. Access to all current external papers, labels, registrations, and mirrors was unattempted, and they were unread; the older separate original sources/trial_families files were not read either.
Verification status: Met
Materials actually read: Summary reading: the material at the exact identified location in the retained source summary was read. The linked external material was not read in this review.
Why unverified: The narrow condition of separately recording current local reading and the actual bibliographic records' (citation) historical access/access dates is verified. This does not mean current verification of external full texts.
Reason for missing information: Current comparison with external original materials was not performed, and access dates/levels are not retroactively reassigned.
Required materials and conditions: Actual access, acquisition, and reading events for each material, original locations and dates, and hashes of the retained inputs
Materials to obtain first: Actual access, acquisition, and reading events for each material, original locations and dates, and hashes of the retained inputs
Further research: Review actions for each material by event/date, and add an actual new external-reading event only when that reading is authorized.
Remaining uncertainty: Current comparison with external original materials was not performed, and access dates/levels are not retroactively reassigned. No new clinical effects, risk rates, individual responses, or grades are calculated or judged.
Conditions for verification: Local retained-summary reading, historical access/access dates for the 13 bibliographic records (citation), the original review date, and current unattempted/unread external access are recorded separately.
Why this condition is needed: Needed to avoid treating historical full-text/abstract/access-failure records (full_text/abstract/access_failure) and original access dates as actions performed in this review.
Application exceptions: Do not describe current unattempted external access as access failure; use a historical access date only for a bibliographic record (citation) that actually has an access_date. Do not mark older separate files as having been read merely because they are referenced.
Referenced methods: C03: the data-collection/selection principles in M04 §4.5–4.6; the distinction between access and reading, and the hyperlink conventions, are internally designed / C09: M04 §4.5, §4.6.3; the limits of the current data conversion follow the user-defined scope and internal design. Reason for adaptation to the comparative HbA1c harm question: needed to avoid treating historical full-text/abstract/access-failure records (full_text/abstract/access_failure) and original access dates as actions performed in this review. No new clinical causality/grade judgment or application of an official method was performed.

Related sources S01 S02 S03 S04 S05 S06 S07 S08 S09 S10 S11 S12 S13

N38 · Are the original C46, 7 axes, document quality, and new condition statuses distinguished in what they describe?

Current findings: The original clinical-harm claim is rated C, 46, with B/S/R1/I0/EX/B2/CX. This is the evidence tier for the increase claim, not risk magnitude, individual response, safety, or document quality. Document-quality grade A (document_quality) is a single-assistant self-review, not external independent certification.
Verification status: Met
Materials actually read: Summary reading: the material at the exact identified location in the retained source summary was read. The linked external material was not read in this review.
Why unverified: The original assessment and what each designation means are verified and preserved in the complete manuscript. This does not issue a new score, grade, risk rate, or declaration that the conditions are sufficient.
Reason for missing information: Gaps in clinical significance/precision remain under the other conditions and are not filled by the original score.
Required materials and conditions: Original records of the assessment, axes, score meaning, document quality, and version
Materials to obtain first: Original records of the assessment, axes, score meaning, document quality, and version
Further research: If a correction becomes necessary, preserve the original event and before/after values, and review criterion revision and changes to the clinical assessment as separate tasks.
Remaining uncertainty: Gaps in clinical significance/precision remain under the other conditions and are not filled by the original score. No new clinical effects, risk rates, individual responses, or grades are calculated or judged.
Conditions for verification: The clinical-harm claim/increase designation (clinical_harm_claim/increase), C46 and B/S/R1/I0/EX/B2/CX, and the meaning of document self-review grade A are each linked to their original locations.
Why this condition is needed: Needed to avoid reusing the original clinical-harm grade as a safety grade, risk rate, document-quality grade, or criterion-fulfillment rate.
Application exceptions: Preserve the original missing values, false values, axes, and score unchanged; do not change them to F or efficacy not_applicable merely because this is a harm claim.
Referenced methods: C01: the question-clarification principles in M03 §3.1, §3.2.1–3.2.4; detailed separation rules are internally designed / C09: M04 §4.5, §4.6.3; the limits of the current data conversion follow the user-defined scope and internal design / H09: Chamgap's own interpretive boundaries. The M19 principles are referenced; no official causality tool was applied. Reason for adaptation to the comparative HbA1c harm question: needed to avoid reusing the original clinical-harm grade as a safety grade, risk rate, document-quality grade, or criterion-fulfillment rate. No new clinical causality/grade judgment or application of an official method was performed.

Related sources S01

N39 · Are the current verification scope, evidence reference date, original server metadata, and update events stated?

Current findings: The original reference date/verification date (verified_date) is 2026-09-15, and the current review date is 2026-10-05. The first-publication date denotes the original editorial issue date, while the deployment timestamp (deployed_at) has no value (null). Update triggers, including matching full texts, plans, corrections, and numerical/classification errors, are retained.
Verification status: Met
Materials actually read: Summary reading: the material at the exact identified location in the retained source summary was read. The linked external material was not read in this review.
Why unverified: Records of dates, scope, server-metadata meaning, and update conditions are distinguished from the actual original values. This does not mean that a current comprehensive literature search or public release was performed.
Reason for missing information: Older original search/selection files were not read, and checks for current external updates were not performed in this review.
Required materials and conditions: Evidence/review dates, actual retained search/selection records, versions, and update/correction events
Materials to obtain first: Evidence/review dates, actual retained search/selection records, versions, and update/correction events
Further research: If authorized new materials become available, compare their identities, dates, original locations, and access levels, and review the linked conditions' observations and status reasons again.
Remaining uncertainty: Older original search/selection files were not read, and checks for current external updates were not performed in this review. No new clinical effects, risk rates, individual responses, or grades are calculated or judged.
Conditions for verification: The original reference date of 2026-09-15, the scope of review of current retained inputs, actual review dates, unverified information, update events, and nondeployment are distinguished.
Why this condition is needed: Needed to avoid overstating conversion of retained materials as a current comprehensive search, completed public release, or absence of studies worldwide.
Application exceptions: Distinguish the historical dates in evidence_cutoff/verified_date from the current review date, and do not interpret the original first-publication date or the missing deployment timestamp (deployed_at, null) as a new deployment event.
Referenced methods: C09: M04 §4.5, §4.6.3; the limits of the current data conversion follow the user-defined scope and internal design / E06: M08 Table 8.2.a, M04 §4.6.3; internal application. Reason for adaptation to the comparative HbA1c harm question: needed to avoid overstating conversion of retained materials as a current comprehensive search, completed public release, or absence of studies worldwide. No new clinical causality/grade judgment or application of an official method was performed.

Related sources